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INTRODUCTION 
 
Voiding dysfunction after pelvic plexus injury occurs most commonly after 
abdominoperineal resection and radical hysterectomy. The true incidence of neurogenic 
vesicourethral dysfunction after various types of pelvic surgery is unknown, because 
there are few prospectively studied series of patients with preoperative and postoperative 
urodynamic evaluation. 
The incidence has been estimated to range from 20 % to 68 % of patients after 
abdominoperineal resection, 16 % to 80 % after radical hysterectomy, 20 % to 25 % after 
anterior resection, and 10 % to 20 % after proctocolectomy [1]. These are estimates 
drawn from past literature and the current incidence is most likely significantly lower, 
owing to the use of nerve-sparing techniques during these types of pelvic surgery. A few 
studies have suggested that the bladder dysfunction after radical hysterectomy may be 
transient and that bladder function may recover to baseline within 6 to 12 months.  
It has been estimated that in 15 % to 20 % of affected individuals, the voiding 
dysfunction is permanent [2]. The injury may occur as a consequent to denervation or 
neurologic decentralization, tethering of the nerves or encasement in scar, direct bladder 
or urethral trauma, or bladder de-vascularization. Neoadjuvant and/or adjuvant 
radiotherapy may play a role as well. The type of voiding dysfunction that occurs is 
dependent on the specific nerves involved, degree of injury and any pattern of re-
innervation or altered innervation that results over time. 
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REVIEW OF LITERATURE 
Neuroanatomy and Neurophysiology of Lower Urinary Tract 
Precise knowledge of neuroanatomy and neurophysiology is important to 
understand to avoid urinary bladder morbidity during pelvic surgery as well as to treat 
lower urinary tract dysfunction.  
Lower Urinary Tract 
The lower urinary tract (urinary bladder and urethra) functions in a co-ordinated 
manner to bring about adequate bladder filling with perfect continence, and periodic 
complete voluntary emptying without any post-void residual urine and without reflux into 
ureter. It executes this function with appropriate sensation, between voluntary voiding up 
to a volume that is sufficient to prevent urinary frequency and without any pain or 
urgency. In the adult the lower urinary tract has voluntary and involuntary neural control, 
but it is normally under voluntary neural control, like defecation, which is clearly 
different from other visceral organs innervated by the autonomic nervous system whose 
regulation is solely by involuntary mechanisms [3]. 
The micturition process can be visualized as a complex of neural circuits in the 
brain and spinal cord that coordinate the activity of smooth muscle in the bladder and 
urethra [4]. These circuits act as on-off switches to alternate the lower urinary tract 
between two modes of operation: storage and elimination. 
The urinary bladder can be divided into two parts: a body lying above the ureteral 
orifices and a base consisting of the trigone and bladder neck, because the two areas are 
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different but homogeneous within themselves regarding neuromorphology and 
neuropharmacology [5]. Histological examination of the bladder body reveals that 
myofibrils are arranged into fascicles in random directions [6]. 
The bladder outlet is composed of the bladder base, urethra, and external urethral 
sphincter. The bladder base has a laminar architecture with a superficial longitudinal 
layer lying beneath the trigone. A muscle layer deep to the superficial layer is continuous 
with the detrusor [7]. The smaller muscle bundles of the deep muscle layer in the bladder 
base exhibit a predominantly circular orientation which is the internal urethral sphincter 
[8]. 
In women, the urethra extends throughout the distal third of the anterior vaginal 
wall from the bladder neck to the meatus. The urethra is composed of tissues that aid 
continence rather than a single discrete and visible ―sphincter.‖ A network of vascular 
sub-epithelial tissue in women contributes to a urethral seal effect [4]. 
The bladder neck serves an important function in reproduction. In men, closure of 
the bladder neck facilitates antegrade ejaculation. This is accompanied through a rich 
noradrenergic innervation by sympathetic nerves that actively contract the bladder neck 
during ejaculation. However, in women, the density of adrenergic innervation in the 
bladder neck is reportedly less than that in men [4]. 
The relationship between bladder shape, size, pressure, and tension was expressed 
by the Laplace law [8]. Marquis Pierre-Simon de Laplace (1779 to 1827) has been called 
the Newton of France. Laplace made the keen observation that the tension in the wall of a 
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container necessary to contain a given pressure is directly proportional to the radius of 
curvature at any point. This is the Laplace law [8]. 
The Laplace equation states that there is a direct relationship between wall tension 
and intravesical pressure and bladder size. In this equation, T is tension, P is intravesical 
pressure, R is urinary bladder radius, and d is wall thickness. During bladder filling,              
P is relatively constant. With a fully distended bladder, d, because of its relative thinness, 
is ignored relative to the other parameters unless a hypertrophied wall exists. Thus, T = P 
× R/2 approximates tension in the full normal bladder [8]. 
The urinary bladder performs several important functions. First, it must store an 
adequate volume of urine. The bladder wall must be able to stretch and rearrange itself to 
allow an increase in bladder volume without significant rise in pressure. In other words, 
the bladder wall must be highly compliant. Second, the smooth muscle and intrinsic 
nerves have to be protected from exposure to urine by the urothelium, which itself must 
also expand readily during filling. Third, bladder emptying requires synchronous 
activation of all the smooth muscle of the bladder body, because if only part of the wall 
contracted, the uncontracted compliant areas would stretch and prevent the increase in 
pressure necessary for urine to be expelled through the urethra.  
Anatomy of Hypogastric, Pelvic Splanchnic and Pudendal Nerve 
The hypogastric nerve is a term for the transition between the superior hypogastric 
plexus and the inferior hypogastric plexus. The hypogastric nerve begins where the 
superior hypogastric plexus splits into a right and left plexus. Each of these divisions is 
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considered a hypogastric nerve. The hypogastric nerve continues inferiorly on its 
corresponding side of the vertebral body, where it descends into the pelvis to form 
inferior hypogastric plexus.  
The superior hypogastric plexus (hypogastric plexus or presacral nerve) which 
receives contribution from T10 to L2 splanchnic nerves is a plexus of nerves situated on 
the vertebral bodies anterior to the bifurcation of the abdominal aorta [4]. 
The inferior hypogastric plexus (pelvic plexus) is a plexus of nerves that supplies 
the viscera of the pelvic cavity.The inferior hypogastric plexus is a paired structure, with 
each situated on the side of the rectum in the male, and at the sides of the rectum and 
vagina in the female [4].Contributions to the plexus include: 
1. A continuation of the superior hypogastric plexus on either side, in the form of the 
hypogastric nerve. 
2. Lumbar splanchnic nerves L3 to L4 
3. Pelvic splanchnic nerves (from the second, third, and fourth sacral nerves) 
contribute parasympathetic efferent fibers to the plexus. 
From these plexuses numerous branches are distributed to the viscera of the pelvis. 
The parasympathetic fibers which arise from pelvic splanchnic nerve (S2-S4) ascend 
from inferior hypogastric plexus, it is more usual for these parasympathetic fibers to 
ascend to the left-handed side of the superior hypogastric plexus and cross the branches 
of the sigmoid and left colic vessel branches, as these parasympathetic branches are 
distributed along the branches of the inferior mesenteric artery [4]. 
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From these plexus numerous branches accompany the branches of the internal 
iliac artery which is the source for the middle rectal plexus, vesical plexus, prostatic 
plexus, and uterovaginal plexus [4]. 
Pelvic splanchnic nerves or Nervierigentes are splanchnic nerves that arise from 
sacral spinal nerves S2, S3, S4 to provide parasympathetic innervation to the pelvic 
viscera. The pelvic splanchnic nerves arise from the anterior rami of the sacral spinal 
nerves S2-S4 and enter the sacral plexus. They travel to their side's corresponding 
inferior hypogastric plexus, located bilaterally on the walls of the rectum [4]. 
From there, they contribute to the innervation of the pelvic and genital organs. The 
nerves regulate the emptying of the urinary bladder, control opening and closing of the 
internal urethral sphincter, influence motility in the rectum as well as sexual functions 
like erection. They contain both preganglionic parasympathetic fibers as well as visceral 
afferent fibers [4]. 
Pudendal nerve (S 2, 3, & 4) is the main nerve of the perineum. It carries 
sensation from the external genitalia of both sexes and the skin around the anus and 
perineum, as well the motor supply to various pelvic muscles, including the external 
urethral sphincter and the external anal sphincter [4]. 
Neural Control of the Lower Urinary Tract 
Peripheral Nervous System 
The lower urinary tract is innervated by three sets of peripheral nerves involving 
the parasympathetic, sympathetic, and somatic nervous systems. Pelvic parasympathetic 
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nerves arise at the sacral level of the spinal cord, excite the bladder detrusor, and relax the 
internal urethral sphincter. Lumbar sympathetic nerves inhibit the bladder detrusor and 
excite the internal urethral sphincter. Pudendal nerves excite the external urethral 
sphincter. These nerves contain afferent (sensory) as well as efferent axons [4]. 
Parasympathetic Pathways 
Parasympathetic preganglionic neurons innervating the lower urinary tract are 
located in the lateral part of the sacral intermediate gray matter in a region termed the 
sacral parasympathetic nucleus [4]. Parasympathetic preganglionic neurons send axons 
through the ventral roots to peripheral ganglia, where they release the excitatory 
transmitter acetylcholine [4]. Parasympathetic postganglionic neurons in humans are 
located in the detrusor wall layer as well as in the pelvic plexus. This is an important fact 
to remember because patients with caudaequina or pelvic plexus injury are neurologically 
decentralized but may not be completely denervated. Caudaequina injury allows possible 
afferent and efferent neuron interconnection at the level of the intramural ganglia [4]. 
Muscarinic Mechanisms 
There are at least five muscarinic receptor subtypes. Pharmacologically, M1, M2, 
and M3 receptor subtypes have been found in the human bladder. Stimulation of M3 
receptors by acetylcholine induces calcium influx through L-type Ca2+ channels, as well 
as IP3 hydrolysis due to phospholipase C activation, resulting in the release of 
intracellular calcium, both of which contribute to a smooth muscle contraction. 
Muscarinic receptor subtype–mediated detrusor contractions shift from M3 to M2 
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receptor subtype has been reported in bladder muscle specimens from neurogenic bladder 
dysfunction patients. 
Sympathetic Pathways 
Sympathetic outflow from the lumbar spinal cord provides a noradrenergic 
excitatory and inhibitory input to the bladder and urethra [9]. Activation of sympathetic 
nerves induces relaxation of the bladder detrusor and contraction of the internal urethral 
sphincter, which contributes to urine storage in the bladder. The peripheral sympathetic 
pathways follow a complex route that passes through the sympathetic chain ganglia to the 
inferior mesenteric ganglia and then through the hypogastric nerves to the pelvic ganglia 
[4]. 
Adrenergic Mechanisms          
 β-Adrenergic stimulated relaxation is mediated through the activation of 
adenylatecyclase and the accumulation of cyclic AMP (cAMP). The β3-adrenergic 
receptor is the most highly expressed subtype among α- and β-adrenoceptor subtypes, and 
β3- receptor agonists are in clinical trial for treatment of detrusor overactivity. In the 
human, there is a predominant expression of α1D receptors present in the normal bladder, 
and the level of expression of α-adrenoceptor mRNA, which is considerably low 
compared with β3 adrenoceptors in normal bladders, was not increased in the bladder 
with outflow obstruction. Urethral tone and intra-urethral pressure are influenced by α-
adrenergicreceptors. The α1A adrenoceptor is the major subtype in the prostate and 
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urethra, and all three α1 adrenoceptor subtypes (α1A, α1B, α1D) are present in blood 
vessels. 
Somatic Pathways 
The external urethral sphincter motor neurons are located along the lateral border 
of the ventral horn, commonly referred to as the Onuf nucleus [10]. Sphincter motor 
neurons also exhibit transversely oriented dendritic bundles that project laterally into the 
lateral funiculus, dorsally into the intermediate gray matter, and dorsomedially toward the 
central canal [10]. 
Afferent Pathways 
Afferent axons in the pelvic, hypogastric, and pudendal nerves transmit 
information from the lower urinary tract to the lumbosacral spinal cord [10]. The primary 
afferent neurons of the pelvic and pudendal nerves are contained in sacral dorsal root 
ganglia (DRG), whereas afferent innervation in the hypogastric nerves arises in the 
lumbar DRG. The central axons of the DRG neurons carry the sensory information from 
the lower urinary tract to second-order neurons in the spinal cord [10].  
Visceral afferent fibers of the pelvic and pudendal nerves enter the cord and travel 
caudally. Pelvic nerve afferents, which monitor the volume of the bladder and the 
amplitude of the bladder contraction, consist of myelinated (Aδ) and unmyelinated (C) 
axons. During neuropathic conditions and possibly inflammatory conditions, there is 
recruitment of C fibers that form a new functional afferent pathway that can cause 
urgency incontinence and possibly bladder pain [10]. 
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Reflex Circuitry Controlling Micturition 
Afferent pathway  Efferent pathways Central pathway 
Urine Storage 
Low-level vesical 
afferent activity (pelvic 
nerve) 
External sphincter contraction 
(somatic nerves) 
Internal sphincter contraction 
(sympathetic nerves) 
Detrusor inhibition (sympathetic 
nerves) 
Ganglionic inhibition (sympathetic 
nerves) 
Sacral parasympathetic outflow 
inactive  
Spinal reflexes 
 
Micturition 
High-level vesical 
afferent activity (pelvic 
nerve) 
Inhibition of external sphincter 
activity 
Inhibition of sympathetic outflow 
Activation of parasympathetic 
outflow to the bladder 
Activation of parasympathetic 
outflow to the urethra 
Spinobulbospinal reflex 
 
 
Multiple reflex pathways organized in the brain and spinal cord mediate 
coordination between the urinary bladder and the urethra. The central pathways 
controlling lower urinary tract function are organized as simple on-off switching circuits 
that maintain a reciprocal relationship between the urinary bladder and the urethral outlet 
[4]. 
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Spinal and Supraspinal Pathways Involved in the Micturition Reflex 
Spinal Cord 
In the spinal cord, afferent pathways terminate on second-order interneuron‘s that 
relay information to the brain or to other regions of the spinal cord, including the 
preganglionic and motor nuclei. Because disynaptic or polysynaptic pathways, but not 
monosynaptic pathways, mediate bladder, urethral, and sphincter reflex, interneuronal 
mechanisms must play an essential role in the regulation of lower urinary tract function 
[4]. 
The micturition reflex can be modulated at the level of the spinal cord by 
interneuronal mechanisms activated by afferent input from cutaneous and striated muscle 
targets. Micturition reflex can also be modulated by inputs from visceral organs [4]. 
Stimulation of afferent fibers from various regions (anus, colon-rectum, vagina, uterine 
cervix, penis, perineum, pudendal nerve) can inhibit the firing of sacral interneurons 
evoked by bladder distention [4]. This inhibition may be a result of presynaptic inhibition 
at primary afferent terminals or be due to direct postsynaptic inhibition of the second-
order neurons.  
Direct postsynaptic inhibition of bladder preganglionic neurons can also be 
elicited by stimulation of somatic afferent axons in the pudendal nerve or visceral 
afferents from the distal bowel [4]. Suppression of detrusor overactivity in patients by 
sacral root stimulation may reflect, in part, activation of the afferent limb of these visceral 
bladder and somatic-bladder inhibitory reflexes [12]. 
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Pontine Micturition Center and Brainstem Modulatory Mechanisms 
Various studies indicate that the micturition reflex is normally mediated by a 
spinobulbospinal reflex pathway passing through relay centers in the brain [4]. The dorsal 
pontinetegmentum has been firmly established as an essential control center for 
micturition in normal subjects. First described by Barrington (1921) [13], it has 
subsequently been called the Barrington nucleus, the pontine micturition center or the M 
region because of its medial location [14]. 
 
Neurons in the PMC provide direct synaptic inputs to sacral preganglionic neurons 
as well as to GABAergic neurons in the sacral dorsal commissure region [14]. The 
former neurons carry the excitatory outflow to the bladder, whereas the latter neurons are 
thought to be important in mediating an inhibitory influence on external urethral 
sphincter motor neurons [14]. In addition to providing axonal inputs to the locus ceruleus 
and the sacral spinal cord, neurons in the pontine micturition center (PMC) also send 
axon collaterals to the paraventricular thalamic nucleus, which is thought to be involved 
in the limbic system modulation of visceral behavior [15]. Some neurons in the PMC also 
project to the periaqueductal gray region (PAG), which regulates many visceral activities 
as well as pain pathways [16]. Thus neurons in the PMC communicate with multiple 
supraspinal neuronal populations that may coordinate micturition with other functions of 
the organism. Although the circuitry in humans is uncertain, brain imaging studies have 
revealed increases in blood flow in this region of the pons during micturition [14]. This 
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change presumably reflects increases in neuronal activity. Thus the PMC appears critical 
for micturition across species [14]. 
Projections from neurons in the lateral pons (L-region or nucleus locus 
subcoeruleus) terminate rather selectively in the sphincter motor nucleus to enhance the 
contraction of pelvic floor muscle and increased urethral pressure during the storage 
phase in cats, providing evidence that this area in the lateral pons functions as ―the 
pontine continence center‖ [17]. Because of these reciprocal connections, the PMC can 
promote bladder–sphincter synergy [17]. 
 
In the midbrain, there is increasing evidence that the mesencephalic PAG, which 
directly receives information of bladder fullness by ascending spinal tract neurons and 
sends projections to the PMC, seems to play an important role in the integration of the 
micturition reflex [14]. The PAG appears to function as a relay center between the PMC 
and spinal cord neurons that are critically involved in the excitatory and inhibitory 
control of the micturition reflex [14]. 
 
Central Pathways That Modulate the Micturition Reflex 
Voluntary control of voiding is dependent on connections between the frontal 
cortex and the septal-preoptic region of the hypothalamus, as well as on connections 
between the paracentral lobule and the brainstem. Lesions to these areas of cortex appear 
to directly increase bladder activity by removing cortical inhibitory control [4]. 
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Physiology of micturition 
The micturition reflex is a finely tuned, coordinated neuromuscular event 
characterized by an orderly physiologic sequence. The two functions of the lower urinary 
tract are the storage of urine within the urinary bladder and the timely expulsion of urine 
from the urethra. The storage and expulsion of urine are part of a complex 
neurophysiologic function that involves autonomic and somatic nervous systems. 
Function is controlled by reflex pathways, which are further modulated by central 
voluntary control.  
The micturition cycle involves two relatively discrete processes: 
(1) Bladder filling and urine storage, and (2) Bladder emptying or voiding. 
Bladder filling and urine storage require: 
1. Accommodation of increasing volumes of urine at low intravesical pressure 
(normal compliance) and with appropriate sensation.  
2. A bladder outlet that is closed at rest and remains so during increases in intra-
abdominal pressure.  
3. Absence of involuntary bladder contractions (detrusor over activity) 
Bladder emptying/voiding requires: 
1. A coordinated contraction of the bladder smooth musculature of adequate 
magnitude and duration.  
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2. A concomitant lowering of resistance at the level of the smooth and striated 
sphincter (no functional obstruction) 
3. Absence of anatomic (as opposed to functional) obstruction 
Bladder response during filling: 
The normal adult bladder response to filling at a physiologic rate is an almost 
imperceptible change in intravesical and detrusor pressure. During at least the initial 
stages of bladder filling, after unfolding of the bladder wall from its collapsed state, this 
high compliance (volume/pressure) of the bladder is due primarily to its elastic and 
viscoelastic properties. Elasticity allows the constituents of the bladder wall to stretch to a 
certain degree without any increase in tension. Viscoelasticity allows stretch to induce a 
rise in tension followed by a decay (―stress relaxation‖) when the filling (stretch 
stimulus) slows or stops. The viscoelastic properties are considered to be primarily due to 
the characteristics of the extracellular matrix in the bladder wall [18].The viscoelastic 
properties of the stroma (bladder wall less smooth muscle and epithelium) and the 
urodynamically relaxed detrusor muscle thus account for the passive mechanical 
properties and normal bladder compliance seen during filling. The main components of 
the stroma are collagen and elastin. In the usual clinical setting, filling cystometry seems 
to show a slight increase in intravesical pressure, but this pressure rise is a function of the 
fact that cystometric filling is carried out at a greater thanphysiologicrate and that, at 
physiologic filling rates, there is essentially no rise in bladder pressure until bladder 
capacity is reached [19].                                                    
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When the collagen component of the bladder wall increases, compliance 
decreases. This can occur with chronic inflammation, bladder outlet obstruction, 
neurologic decentralization, and various other types of injury. Bladder muscle 
hypertrophy, which can result from outlet obstruction, can also result in decreased 
compliance because it is said to be less elastic than normal detrusor; it also can synthesize 
increased amounts of collagen. Once decreased compliance has occurred because of a 
replacement by collagen of other components of the stroma, it is generally unresponsive 
to pharmacologic manipulation, hydraulic distension, or nerve section. Most often, under 
those circumstances, augmentation cystoplasty is required to achieve satisfactory 
reservoir function [4]. 
At a certain level of bladder filling, spinal sympathetic reflexes facilitatory to 
bladder filling / storage are clearly evoked in animals, a concept developed over the years 
by DeGroatet al who has also cited indirect evidence to support such a role in humans 
[4]. This inhibitory effect is thought to be mediated primarily by sympathetic modulation 
of cholinergic ganglionic transmission.  
Through this reflex mechanism, two other possibilities exist for promoting filling/ 
storage. One is neutrally mediated stimulation of the predominantly α -adrenergic 
receptors (α1) in the area of the smooth sphincter, the net result of which would be to 
cause an increase in resistance in that area. The second is neutrally mediated stimulation 
of the predominantlyβ-adrenergic receptors (β3 inhibitory) in the bladder body smooth 
musculature, which would cause a decrease in bladder wall tension. Direct inhibition of 
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detrusor motor neurons in the sacral spinal cord during bladder filling related to increased 
afferent pudendal nerve activity generated by receptors in the striated sphincter. Good 
evidence also seems to exist to support an inhibitory effect of other neurotransmitters 
(e.g. glycine, gamma ammonia butyric acid [GABA], opioids, purines, and the 
noradrenergic system) on the micturition reflex at various levels of the neural axis [4]. 
Outlet response during filling 
There is a gradual increase in urethral pressure during bladder filling, contributed 
to at least by the striated sphincteric element and perhaps by the smooth sphincteric 
element as well. The rise in urethral pressure seen during the filling/storage phase of 
micturition can be correlated with an increase in efferent pudendal nerve impulse 
frequency and in electromyographic activity of the striated sphincter. This constitutes the 
efferent limb of a spinal somatic reflex, the so called guarding reflex, which results in a 
gradual increase in striated sphincter activity during normal bladder filling and storage 
[20].The passive properties of the urethral wall certainly deserve mention because these 
undoubtedly play a role in the maintenance of continence. Urethral wall tension develops 
within the outer layers of the urethra; however, urethral pressure is a product not only of 
the passive characteristics of the elastic, collagenous, and vascular components of the 
urethral wall because this tension must be exerted on a soft or plastic inner layer capable 
of being compressed to a closed configuration-the ―filler material‖ representing the 
submucosal portion of the urethra [21]. 
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Voiding with a normal bladder contraction: 
 Although many factors are involved in the initiation of micturition, in adults it is 
intravesical pressure producing the sensation of distension that is primarily responsible 
for the initiation of normal voluntarily induced emptying of the lower urinary tract. 
Although the origin of the parasympathetic neural outflow to the bladder, the pelvic 
nerve, is in the sacral spinal cord, the actual coordinating centre for the micturition reflex 
in an intact neural axis is in the brainstem. The complete neural circuit for normal 
micturition includes the ascending and descending spinal cord pathways to and from this 
area and the facilitatory and inhibitory influences from other parts of the brain, 
particularly the cerebral cortex. The final step in voluntarily induced micturition involves 
inhibition of the striated sphincter and an inhibition of all aspects of any spinal 
sympathetic reflexes evoked during filling. Efferent parasympathetic pelvic nerve activity 
is ultimately what is responsible for a highly coordinated contraction of the bulk of the 
bladder smooth musculature [22].  
Outlet response during emptying 
A decrease in outlet resistance occurs with adaptive shaping or funnelling of the 
relaxed bladder outlet. Besides the inhibition of any continence promoting reflexes that 
have occurred during bladder filling, the change in outlet resistance may also involve an 
active relaxation of the smooth sphincter area through a non-adrenergic non-cholinergic 
(NANC) mechanism, proposed to be mediated by nitric oxide. The adaptive changes that 
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occur in the outlet are probably also due at least in part to the anatomic interrelationships 
of the smooth muscle of the bladder base and proximal urethra. Longitudinal smooth 
muscle continuity would promote shortening and widening of the proximal urethra during 
a coordinated emptying bladder contraction. Other reflexes that are elicited emptying 
bladder contraction and by the passage of urine through the urethra may reinforce and 
facilitate complete bladder emptying. Superimposed on these autonomic and somatic 
reflexes is complex, modifying supraspinal inputs from other central neuronal networks. 
These facilitatory and inhibitory impulses, which originate from several areas of the 
nervous system, allow the full conscious control of micturition in the adult [22]. 
Urinary Continence during Abdominal Pressure Increases: 
During voluntarily initiated micturition, the bladder pressure becomes higher than 
the outlet pressure and certain adaptive changes occur in the shape of the bladder outlet 
with consequent passage of urine into and through the proximal urethra. One could 
reasonably ask, why do such changes not occur with increases in intravesical pressure 
that are similar in magnitude but that are produced only by changes in intro- abdominal 
pressure such as straining or coughing? [23]. 
First, a coordinated bladder contraction does not occur in response to such stimuli, 
clearly emphasizing the fact that increases in total intravesical pressure are by no means 
equivalent to emptying ability. Secondly, for urine to flow into and through the proximal 
urethra in an individual who does not have sphinctericincontinence, there must be (1) an 
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increase in intravesical pressure that is primarily a product of a coordinated, neutrally 
mediated bladder contraction and that is (2) associated with characteristics tension and 
conformational changes in the bladder neck and proximal urethra [23].  
Assuming that the bladder outlet is competent at rest, a major factor required for 
the prevention of urinary leakage during increases in intra-abdominal pressure is that 
there is at least equal pressure transmission to the proximal urethra ( the midurethra , as 
well as in the female) during such activity. The phenomenon was first described by 
Enhorning (1961) and has been confirmed in virtually every urodynamic laboratory since 
that time. Failure of this mechanism is an invariable correlate of effort- related urinary 
incontinence in the female and male. The urethral closure pressure, indicating that active 
muscular function related to a reflex increase in striated sphincter activity or other factors 
that increase urethral resistance is also involved in preventing such leakage [23].  
Sensory Aspects 
Most of the afferent input from the bladder and urethra reaches the spinal cord 
throughthe pelvic nerve and dorsal root ganglia and some through the hypogastric nerve. 
Afferent input from the striated muscle of the sphincter and pelvic floor travels in the 
pudendal nerve. The most important afferents for initiating and maintaining normal 
micturition are those in the pelvic nerve, relaying to the sacral spinal cord. These convey 
impulses from tension, volume, and nociceptive receptors located in the serosal, muscle, 
and urothelial and suburothelial layers of the bladder and urethra [24]. 
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Pathophysiology of abnormalities of filling/ storage and emptying/voiding:  
Filling/Storage Failure 
Absolute or relative failure of the bladder to fill with and store urine adequately 
results from the bladder overactivity (involuntary contraction or decreased compliance), 
decreased outlet resistance, heightened or altered sensation, or a combination. The 
treatment of filling/storage abnormalities is directed toward inhibiting bladder 
contractility, decreasing sensory output, or mechanically increasing bladder capacity; and 
/or toward increasing outlet resistance, the latter either continuously or just during 
increases in intra-abdominal pressure [25]. 
Emptying/Voiding Failure 
Absolute or relative failure to empty the bladder results from decreased bladder 
contractility (a decrease in magnitude or duration), increased outlet resistance, or a 
combination. The treatment of emptying failure generally consists of maneuvers to 
increase intravesical / detrusor pressure, facilitate the micturition reflex, decrease outlet 
resistance, or a combination. If other means fail or are impractical, intermittent (or 
continuous) catheterization is an effective way to circumvent emptying failure [25]. 
 
Lower urinary tract symptoms [26] 
Lower urinary tract symptoms are divided into three groups, storage, voiding, and             
post-micturition symptoms. 
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Storage symptoms are experienced during the storage phase of the bladder and include 
daytime frequency and nocturia.  
1. Increased daytime frequency is the complaint by the patient who considers that 
he/she voids too often by day  
2. Nocturia is the complaint that the individual has to wake at night one or times to 
void;  
3. Urgency is the complaint of a sudden compelling desire to pass urine which is 
difficult to defer 
4. Urinary incontinence is the complaint of any involuntary leakage of urine. 
Urinary leakage may need to be distinguished from sweating or vaginal discharge.   
a. Stress urinary incontinence is the complaint of involuntary leakage on 
effort or exertion, or on sneezing or coughing.  
b. Urge urinary incontinence is the complaint of involuntary leakage 
accompanied by or immediately preceded by urgency.  
c. Mixed urinary incontinence is the complaint of involuntary leakage 
associated with urgency and also with exertion, effort, sneezing, or 
coughing.   
Enuresis means any involuntary loss of urine. If it is used to denote incontinence 
during sleep, it should always be qualified with the adjective ―nocturnal.‖  
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Nocturnal enuresis is the complaint of loss of urine occurring during sleep.  
Continuous urinary incontinence is the complaint of continuous leakage.  
Other types of urinary incontinence may be situational for example the report of 
incontinence during sexual intercourse, or giggle incontinence.  
5. Bladder sensation can be defined during history taking, by five categories.  
a. Normal: the individual is aware of bladder filling and increasing sensation 
up to a strong desire to void.  
b. Increased: the individual feels an early and persistent desire to void.  
c. Reduced: the individual is aware of bladder filling but does not feel a 
desire to void.  
d. Absent: the individual reports no sensation of bladder filling or desire to 
void.   
e. Non-specific: the individual reports no specific bladder sensation but may 
perceive bladder filling as abdominal fullness, vegetative symptoms, or 
spasticity.   
Voiding symptoms are experienced during the voiding phase.  
1. Slow stream is reported by the individual as his or her perception of reduced urine 
flow, usually compared to previous performance or in comparison to others.   
2. Splitting or spraying of the urine stream may be reported.  
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3. Intermittent stream (intermittency) is the term used when the individual 
describes urine flow which stops and starts, on one or more occasions, during 
micturition.  
4. Hesitancy is the term used when an individual describes difficulty in initiating 
micturition resulting in a delay in the onset of voiding after the individual is ready 
to pass urine.  
5. Straining to void describes the muscular effort used to initiate, maintain or 
improve the urinary stream.  
6. Terminal dribble is the term used when an individual describes a prolonged final 
part of micturition, when the flow has slowed to a trickle/dribble.   
Post micturition symptoms are experienced immediately after micturition.  
1. Feeling of incomplete emptying is a self-explanatory term for a feeling 
experienced by individual after passing urine.  
2. Post micturition dribble is the term used when an individual describes the 
involuntary loss of urine immediately after he/she has finished passing urine, 
usually after leaving the toilet in men, or after rising from the toilet in women 
[26]. 
Urodynamics 
Urodynamics refers to a group of tests used to assess function of the lower urinary 
tract by measuring various aspects of urine storage and emptying. Some specific types of 
urodynamic testing are: 
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1. Cystometry (or cystometrogram) evaluates bladder function by measuring pressure 
and volume of fluid in the bladder during filling, storage, and voiding. 
2. Uroflowmetry measures the rate of urine flow. 
3. Urethral pressure profile tests urethral function. 
4. Leak point pressure determines the bladder or abdominal pressure when leakage 
occurs due to increased abdominal pressure (valsalva or cough) to assess urethral 
resistance. 
5. Post void residual urine. 
The purpose of urodynamic testing is to aid in understanding physiology mechanisms 
of lower urinary tract dysfunction, thereby improving the accuracy of diagnosis and 
facilitating targeted treatment. 
Efficacy 
Clinical evaluation with urodynamics may lead to a more accurate diagnosis of 
incontinence type [27]. A meta-analysis including several thousand women reported the 
symptom of stress incontinence, when compared against an urodynamic diagnosis, was 
91% sensitive, but only 51 % specific in diagnosis pure stress incontinence [27]. For 
urgency incontinence, history alone was 73 %sensitive, but only 55 % specific. In a chart 
review study of women with urinary incontinence, the probability of a change in 
treatment plan with, versus without, urodynamic data was 27% [28]. 
In contrast, a Cochrane review concluded there were insufficient data from 
randomized studies to determine whether treatment of urinary incontinence according to 
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a urodynamic-based diagnosis was more effective than treatment based upon history and 
examination alone [29]. 
Cystometry 
Filling cystometry is the method by which the pressure/ volume relationship of the 
bladder is measured during bladder filling. It is used to assess detrusor activity and 
bladder sensation, capacity, and compliance. Cystometry can be done with one channel 
measuring bladder pressure alone or with an additional channel that simultaneously 
measures abdominal pressure through the rectum or vagina. 
The advantage of the multichannel test is that it can discriminate between changes 
in abdominal versus bladder pressure by electronically subtracting the abdominal 
component from intravesical pressure. 
Only a multichannel test can show that a rise in bladder pressure is due to detrusor 
contraction rather than testing of the abdominal wall. This information is important for 
avoiding a false impression of detrusor over activity. As an example, detrusor over 
activity during single channel cystometry is not reproducible by multichannel test result 
is the most reliable for evaluating women with incontinence [30]. 
Some urodynamic machines can also record urethral pressure with a second sensor 
on the bladder catheter. This allows electronic calculation of urethral closure pressure, 
which is the difference between urethral and bladder pressures. Leakage usually occurs 
when bladder pressure exceeds urethral pressure. However, the clinical value of this 
measurement has not been proven. 
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Indications 
The most common reason to do cystometry is to distinguish detrusor overactivity 
(involuntary contractions of the bladder) from incontinence (leakage due to an increase in 
abdominal pressure). The test can also identify patients with abnormalities of bladder 
sensation and mixed incontinence. 
Modification of cystometry 
1. VideoUrodynamics– This technique is similar to conventional cystometry, but 
with the addition of a radio-opaque filling medium, video recorder, and X-ray 
equipment. Video urodynamics may offer information beyond conventional 
urodynamics in complicated neurologic conditions, but most authorities believe it 
is seldom indicated [31]. The disadvantages are radiation exposure, cost, and the 
extra technical support required. 
2. Ambulatory Urodynamics – Ambulatory testing can be performed by using 
commercially available systems in which an ambulatory patient wears an 
indwelling catheter connected to a microcomputer. The advantage over 
conventional cystometry is that the home environment reflects the patient‘s 
functional status more realistically than the laboratory. Several studies have shown 
the ambulatory urodynamics are more sensitive than conventional urodynamics in 
diagnosing detrusor overactivity [32]. 
Uroflowmetry 
Uroflowmetry measures urine volume voided over time. It can be done with or          
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without a pressure- flow study, which measures detrusor pressure during voiding. 
Indications - Abnormal voiding is much more common in men than in women. 
Nevertheless, uroflowmetry is usually done as part of a complete urodynamic evaluation 
in women. It can be useful in clinical situations, such as 
1. Frequency, urgency, and urgency incontinence as some of these patients have 
outlet obstruction. 
2. Voiding difficulty, hesitancy, or difficulty maintaining the urine stream, which can 
also be due to outlet obstruction (from previous pelvic surgery or urethral kinking 
with anterior vaginal wall prolapsed) or weak detrusor (as in neurologic disease). 
3. Planned pelvic surgery because poor uroflow may be a predictor of postoperative 
voiding difficulty after radical pelvic surgery. This information allows for 
preoperative counselling or training in self-catheterization; however, the predictive 
value of uroflowmetry is controversial of postoperative voiding difficulty [33]. 
Technique  
After the physician and nurse have left the room, the patient voids into a special 
commode that measures the amount and rate of urine flow. Although there are no 
universally accepted standards, a normal uroflow test consists of: 
1. Volume greater than 200 ml over 15 to 30 seconds 
2. Maximum flow rate greater than 15 ml/sec (after correction for artefact) 
3. Continuous single curve (as opposed to short spikes) of flow 
Maximum flow rates < 15ml/sec may indicate obstruction, detrusor weakness 
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or significant valsalva effort during voiding [34]. An acontractile detrusor is unable to 
initiate a contraction and will lead to overflow incontinence. 
Some patients are unable to void normally in the artificial conditions of the 
urodynamics laboratory; thus, it is important to ask the patient if she feels that her void 
was typical for her, especially if an abnormal pattern is observed. If the patient feels the 
test was atypical, it should be repeated. 
Pressure Flow Study 
A pressure-flow study measures both bladder pressure and urinary flow. The 
purpose of a pressure-flow rate is to determine the mechanism of abnormal voiding 
revealed by a low rate on uroflowmetry. If the detrusor pressure is high (>50 cm H2O), 
urethral overactivity (detrusor-sphincter dysynergia) or urethral obstruction (structure or 
tumor) may be present. The most common cause of obstructed voiding in females is 
prolapse of the anterior vaginal wall, which can cause kinking of the pressure-flow study 
in women, is to determine the cause of voiding dysfunction after surgery [35]. 
One study that compared women with bladder outlet obstruction to normal 
controls reported a maximum detrusor pressure >25cm H2O gave the greatest sensitivity 
and specificity, >60% for detection of obstruction [36]. An uroflow, 12ml/sec gave equal 
sensitivity, specificity and accuracy (68 %) for predicting obstruction. 
A pressure flow study can be done as an extension of cystometry when catheters 
are already in place to measure detrusor and abdominal pressure. The patient voids 
around the urethral catheter into a commode, which simultaneously measures uroflow. 
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If the patient has an acontractile or poorly contractile detrusor, she will have a low 
flow rate (<15 ml/ sec maximum flow) and little or no rise in true detrusor pressure. 
Voiding occurs mainly by abdominal straining. Since many patients use valsalva to aid 
voiding, a rise in abdominal pressure alone does not indicate a problem. Detrusor 
acontractility is often due to a neurologic abnormality, such as spinal cord injury or 
multiple sclerosis, but it may be idiopathic. 
Test results are difficult to assess because of the difficulty of voiding around the 
catheter, as well as the artificial surroundings of the urodynamics laboratory. There are 
no accepted standards for the method and interpretation of pressure flow studies. 
Urethral Pressure Profile 
The pressure in the urethra should be equal to or greater than the bladder pressure 
during bladder filling. When the bladder and urethra are in their proper anatomic 
location, increases in intra-abdominal pressure will also increase urethral pressure, 
thereby preventing leakage. Low urethral pressure can be associated with incontinence 
and is related to aging, hypo-estrogenic state, multi-parity, and previous significant 
urogyneological operations. 
The urethral pressure profile (UPP) measures the intraluminal pressure along the 
entire length of the urethra with the bladder at rest. A special catheter with an intravesical 
and an intraureethral pressure transducer and side openings near its tip is perfused and 
slowly withdrawn from the bladder. The transducers are usually brought out to the 
external urethral meatus at a rate of 1 mm/sec by a mechanical pulling device. The 
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pressure necessary to maintain a constant flow provides an assessment of the activity of 
the urethral wall. The clinical purpose of the urethral pressure profile (UPP) is to help 
distinguish intrinsic sphincter deficiency from genuine stress incontinence [37]. 
Leak Point Pressure        
 Abdominal leak point pressure refers to the intravesical pressure at which urine 
leakage occurs due to increased abdominal pressure in the absence of a detrusor 
contraction. The pressure can be produced by valsalva or cough. Unlike the urethral 
pressure profile, the leak point pressure reflects urethral function in the dynamic situation 
that produces incontinence. 
Leak point pressure is used to assess intrinsic sphincter function. It is more reliable 
than the urethral pressure profile for diagnosis of intrinsic sphincter deficiency [38]. 
Post-void Residual Volume        
 This measurement is made either by straight catheterization or by bladder 
ultrasound. Small portable ultrasounds specifically for post-void residual measurement 
are available. A normal patient should have the ability to void at least 80% of the total 
bladder volume and have residual urine <50 mL immediately after voiding. High residual 
urine on repeated determinations indicates outlet obstruction or poor detrusor 
contractility. 
Electro-physiologic testing       
 Various electro-physiologic tests has also been used to evaluate lower urinary tract 
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dysfunction. They have been employed mainly in the context of research, rather than 
clinical care. 
1. Electromyography (EMG) is the study of electrical potentials generated by 
depolarization of muscle. This can be done with surface electrodes, a needle 
inserted into urethral sphincter, a monopolar electrode inside the urethra, a 
concentric needle inserted into the urethral sphincter, or a single fiber to record 
action potentials from individual muscle fibers. 
2. Nerve conduction studies (NCS) examine nerve conduction rates from astimulus 
to a receptor at a distal site. Pudendal nerve terminal motor latency and 
perinealnerve terminal motor latency (the time elapsed between initiating an 
impulse and its arrival at nerves end) can be determined. 
3. Evoked potentials are the sum of potentials recorded in central nervous tissue 
(spinal cord or cortex) after stimulation of a peripheral site such as the perineum. 
Pitfalls in urodynamic testing: 
Numerous pitfalls in urodynamic testing limit its value [39]. Some fundamental 
problems include: 
1. Lack of standardization of technical details, such as patient position, type of 
pressure sensor, and filling rate. These variables significantly affect results. 
2. The artificial situation of the urodynamic laboratory, which produces non 
physiologic results in some patients. 
3. Use of a transurethral catheter can unmask stress incontinence [40]. 
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4. Inconsistent reproducibility of test results in the same patient [41]. 
5. The wide range of physiologic values in normal, asymptomatic patients [42]. 
6. The absence of a specific abnormality during urodynamic testing does not 
exclude its existence, and not all abnormalities found during urodynamics are 
clinically significant. 
 
Radical Hysterectomy 
History of Radical Hysterectomy 
Radical hysterectomy was initially developed as a treatment for cervical cancer 
due to the absence of other modalities of treatment. John Clark performed the first radical 
hysterectomy at John Hopkins Hospital in 1891[43]. Clark and Ries noted the spread of 
cancer to the tissues and lymph nodes beyond the limits of excision of the standard 
hysterectomy. Each of them developed a more radical hysterectomy, removing more of 
the broad ligament, vagina and associated pelvic lymph nodes [43].    
 In 1898, Ernst Wertheim, a Viennese physician, performed the first full extended 
radical operation for cervical cancer. He developed radical total abdominal hysterectomy 
with removal of the uterus, tissues surrounding the upper vagina, pelvic lymph nodes and 
the parametrium [43].  Wertheim did not routinely perform lymphadenectomy, removing 
only clinical enlarged or suspicious nodes. When he reported the outcomes of treatment 
of the first 270 patients, the mortality rate figure was at 18 % and the morbidity rate was 
31% [44].  
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The more radical extension of vaginal hysterectomy was developed by Karl 
Schuchardt of Gottingen and particularly FridrichSchauta of Vienna [43]. In 1901, 
Schauta described radical vaginal hysterectomy and reported a lower operative mortality 
rate than the one of the abdominal approach [44]. The inability to perform adequate 
pelvic lymphadenectomy in the vaginal procedure resulted in the sway of the abdominal 
approach. As a result of the overall, still high mortality rates, radiation therapy replaced 
surgery as the treatment of the choice for cervical cancers [44].   
In 1919, Latzko developed paravesical and pararectal space and divided the 
cardinal ligament wider than Wertheim hysterectomy [45]. In 1921, HidekazuOkabayashi 
proposed his technique of radical abdominal hysterectomy (the same technique of Latzko 
operation, but different management of vesicuouterine ligament), but more as a 
modification of the surgery performed by his teacher Prof. ShouheiTakayama. The 
principles of Okabayashi procedure (i) usage of avascular planes, (ii) cleavage of recto-
uterine ligaments before managing the vascular web and (iii) dissecting the ureter at the 
end of the procedure because of the increased mobility of the uterus[45]. 
In 1941, Mibayashi did total resection of the cardinal ligament with blood vessels 
of the internal iliac artery and vein (ligation of obturator, hypogastric, internal pudendal 
and inferior gluteal artery and vein) [46]. 
In 1954, Joe Vincent Meigs re-popularized the surgical approach when he 
developed a modified Wertheim operation with removal of the pelvic nodes [47]. Meigs 
reported a survival rate of 75% for stage I disease and demonstrated an operative 
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mortality rate of 1%. In 1960, Kobayashi described radical hysterectomy with 
preservation of the pelvic splanchnic nerves [48]. There have been several modifications 
of the operative technique, and in recent years laparoscopy has increasingly been 
employed in the management of early-stage cervical cancer.  
Total laparoscopic radical hysterectomy was done in 1990 by Canis M [49] and in 
1992 by Nezhat C.R [50].The first robotic-assisted radical hysterectomy was reported by 
Sert and Abeler in 2006[51]. Robotic surgery, a new tool in surgical armamentarium is 
designed to remove the limitations of traditional laparoscopy. The advantages of robotic 
radical hysterectomy are improved visualization, improved dexterity and limited fatigue 
and physical discomfort. 
Indications for Radical Hysterectomy 
Radical hysterectomy is performed as a primary therapy for 
1. Stage I B or II A cervical cancer 
2. Selected patients with stage II adenocarcinoma of endometrium with suspected 
endocervical involvement in whom radical surgery seems feasible 
3. Upper vaginal carcinoma, uterine or cervical sarcomas, and other rare 
malignancies confined to the area of cervix, uterus, and/or upper vagina 
Salvage therapy for women with cervical cancer who have been treated with irradiation 
and subsequently develop a small central pelvic recurrence or have a small central area of 
persistent disease. In these cases, the procedure may offer curative salvage treatment as 
an alternate to pelvic exenteration. 
 36 
  
Identification of Basic Components of Surgical Classification: 
There are two common measures of the outcome of the radical hysterectomy. 
First, some adverse effects such as bladder dysfunction correlate with anatomical extent 
of resection and nerve preservation when the pelvic autonomic nerves are threatened as a 
result of the extent of resection. Second, curative effect of surgery correlates with 
anatomical extent of resection, but needs documentation of the balance of benefits and 
risks associated with the procedure. Furthermore, combination of radiotherapy or 
chemotherapy, or both, with radical hysterectomy might negate any real difference in the 
curative effect of the extent of hysterectomy while adversely affecting the frequency of 
complications [52]. 
A classification is not a description of a technique. It is designed to establish the 
surgical template, not the way the surgeon achieves the goal. In 1974, Piver, Rutledge 
and Smith [53]and in 2008, European Organization for research and Treatment of Cancer 
– Gynecological Cancer Group (EORTC–GCG)and Querleu and Morrowclassified 
radical hysterectomy [54]. However, it should include general technical guidelines when 
they are crucial to the success or safety of the operation. 
Classification of radical hysterectomy according to Piver, Rutledge and Smith [53] 
Type I: Extra fascial hysterectomy  
Deflection and retraction of the ureters without dissection of the ureteral bed 
Uterine artery, uterosacral ligament and cardinal ligament are not removed  
No vaginal cuff removed. 
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TYPE II:  Modified radical hysterectomy  
Ureters are freed from the paracervical position but are not dissected out of the 
pubovesicle ligament 
Uterine arteries divided just medial to the ureter 
Uterosacral ligaments resected midway between the uterus and their sacral 
attachments 
Medial half of the cardinal ligaments removed 
Upper one-third of the vagina removed 
Elective pelvic lymphadenectomy 
TYPE III: Classical Meigs’ radical hysterectomy 
Complete dissection of the ureter from the pubovesicle ligament to entry in the 
bladder except a small lateral part so that the superior vesicle artery is conserved 
Uterine artery divided at origin from the internal iliac artery 
Uterosacral ligaments resected at their sacral attachments 
Cardinal ligaments resected at the pelvic wall 
Upper half of the vagina removed 
Routine pelvic lymphadenectomy 
TYPE IV: More radical than type III in the three aspects: 
Complete dissection of the ureter from the pubovesical ligament 
 The superior vesicle artery is sacrificed 
Upper 3 quarters of the vagina removed 
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TYPE V: More radical than type IV: 
Excision of involved portion of distal ureter or bladder and re-implantation of 
ureter into the bladder 
Classification of radical hysterectomy according to Querleu and Morrow, [52] 
Type A   
Extrafascial hysterectomy  
Visualisation and /or palpation of ureters without dissection of the ureteral bed 
Uterine artery, uterosacral ligament and cardinal ligament are not transacted at a 
distance from the uterus 
Minimal vaginal cuff removed (<10mm) 
Type B 
Ureters are unroofed and rolled laterally 
Partial removal of uterosacral and vesicouterine ligaments 
Transaction of the paracervix at the level of the ureteral tunnel 
At least 10 mm of the vagina from the cervix or tumor is resected 
Type B1: without removal of the lateral paracervical lymph nodes 
Type B2: with additional removal of lateral paracervical lymph nodes 
Type C 
Ureters are completely mobilized 
Transection of the uterosacral ligament at the rectum 
Transection of the vesicouterine ligament at the bladder 
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Complete transection of the paracervix 
15 – 20 mm of the vagina from the cervix or the tumor and the corresponding 
paracolpos is resected routinely 
Type C1: with preservation of autonomic nerves 
Type C2: without preservation of autonomic nerves 
Type D 
Type D1: resection of the entire paracervix at the pelvic side wall together with the 
hypogastric vessels, exposing the roots of the sciatic nerves 
Type D2: type D1 plus resection of the entire paracervix at the pelvic side wall the 
hypogastric vessels and adjacent fascial or muscular structures 
For all types, lymphadenectomy is described separately according to four levels. 
L 1 - external and internal iliac nodes 
L 2 – common iliac nodes 
L 3 – aortic inframesentric nodes 
L 4 – aortic infrarenal nodes 
Nerve sparing technique of radical hysterectomy [55,56] 
The nerve sparing technique, by laparotomic or laparoscopic route, includes 4 main steps:  
1. The preservation of the superior hypogastric plexus at the level of the presacral 
area during the presacral lymphadenectomy;  
2. The preservation of the hypogastric nerve dorsal to the ureter and lateral to the 
utero-sacral ligament during the section of the utero-sacral ligaments;  
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3. The preservation of the inferior hypogastric plexus during the section of the 
cardinal ligament, since the plexus lie dorsal to the parametrial vessels at the level 
of the deep uterine vein; and 
4. The preservation of the bladder branch during the section of the deep layer of 
the cervico-vesical ligament.  
Two main approaches have been proposed:  
1. The identification of the hypogastric nerve followed by the section of the 
parametria medial to the nerve [55], this obtains a type 2;  
2. The identification, clipping and section of the parametrial vessels at the level 
of the pudendal vessels, followed by the identification of the hypogastric nerve 
near to the utero-sacral ligaments and its separation from the fibrous part of the 
cardinal ligament; this technique obtains a type 3-4 [56]. 
Intraoperative and Postoperative Urological Complications of Radical 
Hysterectomy 
With meticulous surgery, intra-operative injury to the urinary tract during radical 
hysterectomy is rare. The incidence of the following complications depends on the stage 
of the disease and the radicality of the procedure [57] 
1. Intra-operative injury of the bladder and ureters: Almost in all cases of 
bladder or ureteral injury, the disease was relatively more invasive, for example 
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stage II B with cancer reaching the bladder or ureter, which are then sutured 
directly or require ureteral re-implantation [57] 
2. Postoperative fistula formation: Radical hysterectomy requires the dissection of 
the entire pelvic course of the ureter, which may result in the interruption of 
several arterial branches that provide its blood supply [58]. Most fistulas result 
from postoperative ischemia, not from injury [57]. The incidence of vesicovaginal 
and ureterovaginal fistula formation about 0.6% - 6.6% has been reported. The 
fistulas usually appear between   12
th
 – 14th postoperative days. The most common 
symptom exhibited by patients who developed ureterovaginal fistula is 
spontaneous leakage of urine from the vagina. The ureterovaginal fistula is usually 
located in the lower third of the ureter. One must wait for two to six months to 
repair the fistula. Based on experience, waiting for at least six months after 
operation has resulted in not only spontaneous healing but also more successful 
repair [58]. 
3. Ureteric stricture formation is also a potential hazard following radical 
hysterectomy, and should also be borne in mind when follow-up of patients treated 
with radical hysterectomy [59]. 
The Functional Alteration of Urinary Bladder and Urethra after Radical 
Hysterectomy 
Postoperative lower urinary tract dysfunction is common among patients who 
undergo radical hysterectomy. Sensory loss and voiding disorders are the primary 
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complaints. These complications relate to nerve damage to the pelvic plexus and pelvic 
organs. During radical hysterectomy, parasympathetic denervation may occur if the 
surgeon strips the sacral nerves bilaterally or excises a major portion of the paracervical 
and paravaginal webs of retroperitoneal tissue. The sympathetic nerves are also 
vulnerable to injury during dissection of bilateral lymph nodes [60]. 
The pelvic plexus formed by the confluence of pelvic parasympathetic nerves with 
sympathetic hypogastric nerves, and also contains ganglia where parasympathetic and 
sympathetic nerves interact synchronously [61]. With nerve trunks emanating from S2-4, 
the pelvic plexus occupies the area of the inferior segment of the cardinal ligament. The 
urethra and bladder are connected to the terminal branches of the pelvic plexus [62]. 
Impaired micturition after a radical hysterectomy may result from altered 
modulation by the pelvic plexus and the resulting motor and sensory impairment of the 
detrusor [63]. Impaired detrusor contraction may be secondary to improper sensory input 
to the sacral and cortical micturition centres [64]. The combination of the failure to 
trigger the detrusor reflex and the urethral relaxation reflex results in detrusor 
underactivity and a nonrelaxing urethral sphincter which manifests as a voiding 
dysfunction. Normal urinary sensation is lost, and such patients depend on substitute 
sensations (i.e., fullness in the abdomen, tension in the pelvic region, a vague feeling of 
discomfort), which they gradually learn to associated with a full bladder [65]. The 
patients have to void at regular intervals and learn to stimulate the intrinsic 
neuromuscular mechanism by straining and other manipulations that allow them to void 
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by relaxing the voluntary sphincter [66]. However, voiding by straining is not a 
physiologic voiding method, and depends on the patient's abdominal muscle effort. It 
may compensate incompletely for the detrusor acontractility and urethral resistance [65]. 
Dysuria, chronic urinary retention, overflow incontinence, and frequent urinary tract 
infection are the common symptoms accompanying a voiding dysfunction. Some of the 
patients also need clean, intermittent self-catheterization [65]. 
In addition to impaired urinary bladder sensation and difficulty in micturition, 
urinary incontinence is also a common complaint of patients who undergo radical 
hysterectomy. A deficit in bladder neck support and the partial loss of alpha-adrenergic 
tone in the proximal urethra may result from the radical resection of the upper vagina and 
parametrium if there is damage to part or the pelvic plexus, resulting in a transaction of 
urethral sympathetic innervations [66]. Axelsen etal recently reported that the urethral 
sphincter mechanism plays a role in the pathophysiology, rather than the mobility of the 
bladder neck [67]. Bladder neck incompetence and low urethral closure pressure 
contribute to overflow incompetence and low urethral closure pressure contribute to 
overflow incontinence or urinary stress incontinence, which are exacerbated when 
combined with poor bladder compliance. The reduction in bladder compliance on filling 
may be due to a loss of sympathetic beta-adrenergic innervations with its inhibition and 
relaxation of the detrusor muscle [63]. Chronic urinary tract infection may also cause 
decreased bladder compliance [68].  
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Functional changes to the bladder and urethra after radical hysterectomy are multi-
factorial. Anatomical changes and irreversible visceral damage after extensive 
dissections, as well as neurological alterations, may account for the resulting lower 
urinary tract dysfunction [69]. In other cases, pre-existing abnormal urinary tract function 
may worsen after radical hysterectomy [70]. Lin et al reported that up to 83% of patients 
with cervical cancer had abnormal urodynamic findings before radical hysterectomy [71]. 
Chen et al noted that the rate of detrusor instability before treatment in women with 
cervical carcinoma was higher than that of a control group with carcinoma-in-situ            
(CIN 3) (37.5% vs. 14.8%, p <0.05) [72]. 
Urodynamic studies have made these functional disorders quantifiable. In 1949, 
Halter and Richter reported cystometric studies demonstrating a hypertonic bladder with 
reduced capacity in the early postoperative period. These findings have been confirmed 
by a number of authors [57, 64, &69]. Immediate postoperative hypertonic and poorly 
compliant bladder is believed to be related to perivesical adhesions and intrinsic 
myogenic tone change [73]. Overdistention in the early postoperative period should be 
avoided, for not only does it precipitate bladder atony but evidence also suggests that it 
may cause urinary fistulas [74]. 
Kuoet at performed urodynamic studies on 47 patients with cervical cancer who 
underwent radical hysterectomy and bilateral lymphadenectomy to assess the functional 
alteration of the bladder and urethra at different stages [69]. All patients developed 
hypertonic, poorly compliant bladder and reduction in urethral closure pressure before 
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bladder training was begun. After 3 to 6 months, 3 different types of cystometric change 
were noted. Twenty-five patients (53.2%) had hypotonic and acontractile bladders with 
enlarged capacity while 15 (31.9%) had better compliant bladder with normal tone but 
still had difficulty emptying the bladder. The remaining 7 patients (14.9%) maintained 
the immediate postoperative hypertonic state. Reduction of maximal urethral closure 
pressure was noted in 29 (61.8%) patients, remained unchanged in 13 (27.6%) and 
increased in 5 (10.6%). 43 patients had diminished or absent sensation of bladder 
fullness, and all except one complained of dysuria. The different urethral pressure 
changes and different cystometric changes documented in this study may reflect a more 
complicated mechanism after complete or incomplete denervation of autonomic nerves 
that control the lower urinary tract[69]. 
Generally, acute voiding symptoms disappeared within 6 to 12 months after 
radical hysterectomy [73]. However some authors have reported that 20% to 50% of 
similar patients have persistent urinary symptoms, mainly urinary incontinence, impaired 
bladder sensation, urinary tract infections, and straining to void [59]. Improvement of 
clinical symptoms alone was an unreliable indicator of improved function, since lower 
urinary tract dysfunction may be relieved by compensatory factors such as substitute 
sensations, abdominal straining, voiding technique, and the condition of the bladder 
outlet [73]. Such patients are permanently susceptible to decompensation, especially if 
placed in circumstances that promote bladder overdistention[74]. 
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Dwyer et al investigated long-term symptomatic and urodynamic changes 
occurring in women with established urinary dysfunction after radical hysterectomy [75]. 
The only symptom that showed significant improvement over time was impaired 
sensation. There was no significant change in any of the urodynamic parameters between 
the initial and follow-up assessments. According to the study results, there was little 
improvement over time in urinary dysfunction following radical hysterectomy [75]. 
Methods for Minimizing Urinary Bladder Morbidity 
Radicality is closely related to postoperative morbidity. Zullo et al recently noted 
that the extent of vaginal resection was more strongly associated with bladder 
dysfunction than was the extent of the lateral parametrial resection [76]. Lower-risk 
patients, i.e., those with smaller-volume tumors and in the early stages might benefit from 
modified radical hysterectomy (class II) which have been shown to cause less voiding 
dysfunction without compromising disease-free survival [77]. The type of the procedure 
may be different on each side of the cervix if tumor growth is asymmetrical [52] 
Direct, nerve-sparing radical hysterectomy is a technique that spares the pelvic 
autonomic nerves without compromising radicality, providing another approach to 
improving quality of life and reducing bladder and bowel morbidity [77]. A number of 
studies have shown such surgical technique to be feasible with satisfactory recovery of 
voiding function [78, 79]. Raspagliesi et al reported that the type III nerve-sparing radical 
hysterectomy seems to be comparable to type II radical hysterectomy and superior to type 
III radical hysterectomy in terms of reducing early bladder dysfunction [80]. Todo et al 
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assessed postsurgical bladder function, 22 patients treated for cervical cancer with nerve-
sparing radical hysterectomy by urodynamic study. There was no significant difference in 
compliance, maximal flow rate, and residual urine volume before the operation and at 12 
months after the operation. This surgical technique is thought to be effective for 
preservation of bladder function [81]. 
The technique of sparing the pelvic autonomic nerves during radical hysterectomy 
for early stage cervical cancer and clinical stage II endometrial cancer is comparable to 
the conventional method in terms of perioperative complications and morbidity, but is 
more favorable in terms of return of bladder function [82]. 
Ditto A et al, compared class III nerve sparing radical hysterectomy (NSRH) 
compared with standard radical hysterectomy (RH) in cervical cancer (CC) in the context 
of multimodal therapies to evaluate disease-free survival, overall survival, local 
recurrence rate, and morbidities, in which total of 496 patients were enrolled and the 
median follow up was 93 months (42 and 159 months for the NSRH and RH groups, 
respectively) [89]. The oncologic results were comparable between NSRH and 
conventional class III RH in the context of two multimodal treatments. Bladder function 
and postoperative complications rate are improved by nerve sparing technique. The nerve 
sparing technique should be considered in all carcinoma cervix patients addressed to 
radical hysterectomy because it improves functional outcome and preserves radicality 
without compromising overall survival [83]. A recent meta-analysis demonstrated lower 
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incidence of LUTD following nerve sparing radical hysterectomy compared to 
conventional radical hysterectomy [84]. 
However, there are no standardized techniques for the nerve sparing approach. 
Urinary functional outcome varies according to the technique used and the different 
approaches to clear the ligament and the lymph nodes from the nerves. Laparoscopic and 
robotic approaches appear to facilitate the preservation of pelvic nerves by allowing a 
fine and precise dissection in a magnified operative field and are associated with better 
functional outcomes [85].  
Unilateral nerve sparing approach is also associated with lower incidence of 
LUTD demonstrating that unilateral nerve injury could be partially compensated by the 
nervous supply from the other side [86].  
In addition, there are different neural injuries with different prognosis. The injury 
could be a temporary blockade of signal transmission without axon lesion (neurapraxia) 
with functional disorders resolving hours to weeks following surgery. It could be a 
transection of the axon with intact nerve sheets (axonotmesis) allowing regeneration at 
the site of the injury and distal to the injury with a nerve growth velocity varying from 
0.25mm/day to 4mm/day. A complete transection of the nerves including their sheets is 
also possible with no potential to regenerate [87]. The mechanism is even more complex 
because injury of vascular supply to these nerves is as much important as injuries to the 
nerves themselves [88]. The combination of stretch and ischemia makes the nerve more 
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vulnerable to injury. It appears that to obtain optimal functional results avoiding nerve 
handling in nerve sparing approach should be mandatory [88].  
Finally, nerve injury is not the only mechanism responsible for LUTD after radical 
hysterectomy as demonstrated by the higher incidence of LUTD following type 4 nerve-
sparing radical hysterectomy. Direct surgical injury to the bladder wall, lymph stasis, 
interruption of the blood supply, and fibrosis of the urethra also play a role [89]. 
A laparoscopic approach to reduce immediate postoperative morbidity has been an 
attractive prospect to surgeons in recent years [90]. 
 
Laparoscopic Radical Hysterectomy  
Total laparoscopic radical hysterectomy for cervical carcinoma is an accepted 
modality not only because of its technical feasibility but also because of its oncologic 
outcomes [91]. However, bladder dysfunction after laparoscopic radical hysterectomy 
was actually increased without nerve sparing. Nerve-sparing techniques have been 
established to maintain postoperative quality of life. The hypogastric nerves are regarded 
as the anatomical landmark to accomplish total laparoscopic nerve-sparing radical 
hysterectomy. Bladder function following conventional total laparoscopic nerve-sparing 
radical hysterectomy is maintained. However, in some cases the radicality of this 
procedure is insufficient. Therefore, its applicability is expected to be limited to early 
stage cervical carcinoma [92]. Greater radicality is necessary for intermediate and 
advanced stage cervical carcinoma and may not permit nerve sparing in such cases[92]. 
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Types of total laparoscopic radical nerve sparing hysterectomy [93] 
1. Conventional nerve-sparing technique – Both sides hypogastric nerve and pelvic 
nerve plexus was preserved completely 
2. Radical nerve-sparing technique – Both sides hypogastric nerves were sacrificed 
and pelvic splanchnic nerves were partially preserved 
3. Non-nerve-sparing technique – Both sides hypogastric nerve and pelvic splanchnic 
nerves were completely sacrificed 
The sensory nerve is distributed predominantly at the lower (dorsal) half of the pelvic 
nerve networks. The motor nerve is distributed predominantly at the upper (ventral) half 
of the pelvic nerve networks. The first sensation of bladder filling is weak and 
inconsistent, and is possibly dependent on cortical fluctuation. Impulses related to the 
first desire to void traverse through the pelvic nerves, and impulses for the sensation of a 
full bladder (strong desire to void) traverse through the pudendal nerves [94]. Therefore, 
first desire to void as the most effective parameter to evaluate bladder sensory function 
after the nerve-sparing procedure.  
The sensory functions of conventional and radical nerve-sparing technique are 
statistically equivalent, and the sensory function of non-nerve-sparing technique is 
significantly lower than that of conventional and radical nerve-sparing technique. In 
contrast, the motor nerve is distributed predominantly at the upper (ventral) half of the 
pelvic nerve networks. Therefore, the motor function of conventional nerve-sparing 
technique is significantly more preserved compared to that of radical nerve-sparing and 
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non-nerve-sparing technique [93]. The motor functions of radical nerve-sparing and non-
nerve-sparing technique are damaged similarly; they show no mutually significant 
difference. The various types of total laparoscopic nerve-sparing radical hysterectomies 
are technically feasible, and they can be tailored to the stage of cervical cancer [93]. 
 
Robotic Radical Hysterectomy  
The clinical impact of robotic surgery in gynecologic field is growing widely, as 
suggested by a recent consensus statement made by the Society of Gynecologic Oncology 
in 2012 [95]. The society has stated that the current evidence supports at least an 
equivalence of robotic surgery and laparoscopy in many perioperative outcomes. 
However, there is a lack of disease specific oncologic outcomes and the cost is still a 
potential barrier to the widespread acceptance of robotic surgery [96]. Nevertheless, the 
number of robotic surgeries is growing and the implementation of robotic surgery in 
gynecologic oncology has made a dramatic change in the proportion of minimally 
invasive surgery, ranging from 3.3% to 43.5%, as shown in a study by Hoekstra, et al 
[97]. A recent meta-analysis indicated that comparison of robotic and conventional 
laparoscopic surgery was not feasible due to insufficiency in studies that assessed proper 
‗radical‘ hysterectomy solely for cervical cancer. Surgical outcomes of RRH and pelvic 
lymphadenectomy were comparable to that of laparoscopic approach, with favorable 
outcomes in regards to intraoperative blood loss and postoperative complications [98]. 
 
 52 
  
Therapy to Facilitate Urine Storage/Bladder Filling: [3] 
Bladder related (inhibiting bladder contractility, decreasing sensory input, and/or 
increasing bladder capacity) 
I. Behavioral therapy including any or all of the following: 
1. Education  
2. Bladder training 
3. Timed bladder emptying or prompted voiding 
4. Fluid restriction 
5. Pelvic floor physiotherapy ± biofeedback 
II. Pharmacologic therapy (oral, intravesical, intradetrusor) 
1. Anti-cholinergic agents 
2. Drugs with mixed actions 
3. Calcium antagonists 
4. Potassium channel openers 
5. Prostaglandin inhibitors 
6. β-Adrenergic agonists 
7. α-Adrenergic antagonists 
8. Tricyclic antidepressants; serotonin and norepinephrine reuptake inhibitors 
9. Dimethyl sulfoxide (DMSO) 
10. Polysynaptic inhibitors 
11. Capsaicin, resiniferatoxin, and like agents 
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12. Botulinum toxin 
III. Bladder overdistention 
IV. Electrical stimulation and neuromodulation 
V. Acupuncture and electroacupuncture 
VI. Interruption of innervation 
1. Very central (subarachnoid block) 
2. Less central (sacral rhizotomy, selective sacral rhizotomy) 
3. Peripheral motor and/or sensory 
VII. Augmentation cystoplasty (auto, bowel, tissue engineering) 
 
Outlet Related (Increasing Outlet Resistance) 
I. Behavioral therapy 
1. Education 
2. Bladder training 
3. Timed bladder emptying or prompted voiding 
4. Fluid restriction 
5. Pelvic floor physiotherapy ± biofeedback 
II. Electrical stimulation 
III. Pharmacologic therapy 
1. α-Adrenergic agonists 
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2. Tricyclic antidepressants; serotonin and norepinephrine 
reuptake inhibitors 
3. β-Adrenergic antagonists, agonists 
IV. Vaginal and perineal occlusive and or supportive devices; urethral plugs 
V. Nonsurgical periurethral bulking 
VI. Collagen, synthetics, cell transfer (tissue engineering) 
VII. Vesicourethral suspension ± prolapse repair (female) 
VIII. Sling procedures ±  proposal repair (female) 
IX. Closure or compression of the bladder outlet (balloons, surgical closure) 
X. ―Sling/Tape‖ procedure (male) 
XI. Artificial urinary sphincter 
XII. Bladder outlet reconstruction 
XIII. Myoplasty (muscle transposition) 
XIV. Circumventing the problem 
1. Absorbent products 
2. External collecting devices 
3. Anti-diuretic hormone like agents 
4. Short acting diuretics 
5. Intermittent catheterization 
6. Continuous catheterization 
7. Urinary diversion 
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Therapy to Facilitate Bladder Emptying/Voiding 
Bladder related (increasing intravesical pressure or facilitating bladder 
contractility) 
I. External compression, Valsalva 
II. Promotion or initiating of reflex contraction 
1. Trigger zones or maneuvers 
2. Bladder ―training‖; tidal drainage 
III. Pharmacologic therapy (oral, intravesical) 
1. Parasympathomimetic agents 
2. Prostaglandins 
3. Blockers of inhibition 
i. α-Adrenergic antagonists 
ii. Opioid antagonists 
IV. Electrical stimulation 
1. Directly to the bladder or spinal cord 
2. Directly to the nerve roots 
3. Intravesical (transurethral) 
4. Neuromodulation 
V. Reduction cystoplasty 
VI. Bladder myoplasty (muscle wrap) 
VII. Tissue engineering 
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Outlet related (Decreasing outlet resistance) 
I. At level of smooth sphincter 
1. Pharmacologic therapy - α-Adrenergic antagonists, β-Andrenergic agonists 
2. Botulinum toxin (injection) 
3. Transurethral resection or incision 
4. Y-V plasty 
II. At level of striated sphincter 
1. Behavioural therapy ± biofeedback 
2. Pharmacologic therapy 
i. Benzodiazepines 
ii. Baclofen 
iii. Dantrolene 
iv. α-Adrenergic antagonists 
v. Botulinum toxin (injection) 
3. Urethral stent 
4. Pudendal nerve interruption 
III. Circumventing the problem 
1. Intermitted catheterization 
2. Continuous catheterization 
3. Urinary diversion (conduit) [3]. 
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AIM 
 
The aim of this study was to analyze subjectively and objectively the urinary bladder 
morbidity in terms of voiding dysfunction following type III radical hysterectomy for 
carcinoma uterine cervix. 
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METHODS AND MATERIAL 
This study was conducted after obtaining permission from the Institutional Ethics 
Committee, and it was in accordance with the Declaration of Helsinki & Good Clinical 
Practice (GCP) guidelines. Patients with cervix or carcinoma endometrium were 
explained about the study purpose and procedures. Informed consent was obtained in the 
language understandable to the individual. 
Study type - Prospective study 
Study period - January 2013 to January 2015 
Sample size - 51 patients 
Study population – Women diagnosed as carcinoma cervix or carcinoma endometrium. 
Inclusion Criteria: 
1. Age: 18 to 70 years 
2. Carcinoma cervix up to Stage II with or without preoperative therapy 
3. Carcinoma endometrium with endocervical involvement 
4. Patients who underwent type III radical hysterectomy with curative indent 
Exclusion Criteria: 
1. Patients with preoperative urinary symptomatology (urgency, straining, urinary 
incontinence, dysuria) 
2. Abnormalities in preoperative uroflowmetry 
3. Patients with previous lower urinary tract surgery 
4. Patients not willing to give informed consent  
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5. Patients not willing to do uroflowmetry in 1, 3, and 6 month 
Study procedure: 
Individuals who fulfilled the inclusion and exclusion criteria were enrolled to enter 
this study. All the patients underwent a complete clinical examination, including per 
vaginal and digital rectal examination and relevant radiological including chest X-ray and 
CT/MRI of abdomen and pelvis and other investigations required for diagnosis and 
staging. Multidisciplinary evaluations were done as indicated. Pre-anesthesia fitness was 
taken for all patients before surgery. Relevant history, co-morbidities, previous treatment 
and family history were obtained. All the patients were staged according to FIGO staging 
system after histopathological proof of cancer by biopsies. Patients received treatment 
according to their cancer site and stage as per standard practice. Open Type III Radical 
hysterectomy was done with standard surgical oncological principles. 
A baseline screening for urinary bladder function was done at the diagnosis of 
disease prior to start of preoperative treatment, if any before radical hysterectomy 
followed by postoperative evaluation of bladder function was done at 1
st
 month, 3
rd
 
month and 6
th
 month with urinary symptomatology (straining, urinary incontinence, 
urgency, and dysuria) and uroflowmetry (voided volume, maximum flow rate & average 
flow rate) and post-voided residual volume with ultra-sonogram. The patients who 
presented with incontinence in the first visit were educated about and encouraged to 
perform pelvic floor exercises. Patients were followed up for subsequent management of 
urinary problems, if any.  
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Statistical Analysis:  
The variables investigated included age, body mass index, primary cancer, clinical 
stage, neoadjuvant or adjuvant therapy, urinary symptomatology (straining, incontinence, 
urgency, dysuria), parameters of uroflowmetry (voided volume, maximum flow rate, 
average flow rate), and post-void residual urine and needed catheterization. 
 Standard statistical tests Fischer exact test for categorical values and Wilcoxon 
signed rank test for sequential continuous variable were used for analysis. All the data 
were expressed as mean ± SD or in percentage as needed. The differences were 
considered to be significant if p value < 0.05. 
 
Uroflowmetry:  
Uroflowmetry is a test that measures the total voided volume of urine over time. 
This test is useful in evaluating the function of the lower urinary tract. Uroflowmetry is 
non-invasive and inexpensive test. It is easy to perform and quickly provides data on both 
storage and voiding symptoms. The addition of a non-invasive post-void residual volume 
measurement by ultrasound adds to the value of the study.  
These studies were conducted with as much privacy as possible, and patients were 
asked to void urine when they feel a normal desire. The patients were instructed to 
urinate in a special urinal equipped with a computer machine that records the uroflow 
parameters. The patients were asked to press a button shortly before beginning urination, 
and to press the button again after finishing.  
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Preparation: 
Uroflowmetry is best performed with full bladder. The patients were instructed not 
to urinate for 2 hours prior to the test. The patients were instructed to increase the volume 
of fluids they drink so as to have plenty of urine for the test.  
Risks:  
As the test involves normal urination and no invasive procedure, patients did not 
experience any discomfort. There was no risk associated with this test.  
Normal Valves in Uroflow: 
The maximum flow rate (Q max) is volume dependent, only voided volume of 
atleast 150 ml. should be interpreted [99]. The maximum flow rate should always be 
documented together with the total voided volume and post-void residual volume with 
the following standard format: maximum flow rate, volume voided, and post-void 
residual volume.  
Normal uroflow parameter in a young man is Q max greater than 15-20 ml/sec and 
less than 10 ml/sec is abnormal. These numbers decline with age by 1-2 ml/sec per 5 
years. There is a decline in peak flow with age resulting in a maximum flow of 5.5 ml/sec 
at 80 years [100]. 
Normal uroflow parameters in womenQ max can be greater than 30 ml/sec, and 
less than 15 ml/sec is abnormal [101]. Maximum flow in women does not seem to be 
dependent upon age. Women have a very short urethra, minimal outlet resistance, and no 
prostate, and generally speaking the only factors influencing female uroflow are the 
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strength of the detrusor muscle and the urethral resistance and the degree of relaxation of 
the sphincter mechanism [101].  
Normal voiding includes a detrusor muscle contraction, co-ordinate bladder outlet 
relaxation, low voiding pressure, a smooth, arc-shaped flow curve [102]. The flow 
pattern, that is, the shape of the flow tracing, can sometimes be used to make a 
presumptive diagnosis, although it cannot be used to make a definitive diagnosis. The 
normal flow pattern is a continuous, bell-shaped smooth curve with a rapidly increasing 
flow rate [102].  
Abnormal Uroflowmetry: 
An intermittent flow pattern is one that has one or several episodes of flow 
increasing or decreasing (or ceasing completely) and is commonly secondary to 
abdominal straining or external sphincter spasm (e.g., detrusor-sphincter dys-synergia). 
The typical obstructed flow pattern has a plateau-shaped curve with a prolonged flow 
time, sustained low flow rate, and increased time to Q max. Abnormal results indicate 
urinary bladder morbidity which may be abnormal detrusor muscle contraction or 
uncoordinated bladder outlet relaxation but cannot distinguish true obstruction from poor 
detrusor contractility [103]. Maximum flow rate < 15 ml/sec may indicate detrusor 
weakness or outlet obstruction or both [10].  
Post-void Residual Urine: 
At the end of the urination, immediately after uroflowmetry, transabdominal 
ultrasound was done and the bladder was scanned in two planes and the three diameters 
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were measured. The formula for post-void residual urine used was: multiplying the 
products of three diameters (height × width × depth) by 0.625, a corrective factor as the 
bladder only approaches a spherical shape when it is full was to be applied [104]. 
Ultrasound obviates the need for urinal catheterization with its risk of introducing 
infection.  Post-void residual urine ≥ 50 ml is abnormal.  
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RESULTS 
In this study 51 patients underwent Type III radical hysterectomy (including 
bilateral pelvic lymph node dissection) with preoperative and postoperative evaluation of 
voiding dysfunction symptoms, uroflow parameters and post-void residual urine at 1
st
, 
3
rd
, and 6
th
 month.  Data were expressed either in percentage or mean ± standard 
deviation as appropriate.  
Table 1 - Baseline characteristics 
Diagnosis Patients Age (years) BMI 
Carcinoma cervix 46 (90.2%) 49.04±9.51 20.11±2.03 
Carcinoma endometrium with 
endocervical involvement 
5 (9.8%) 56.20±7.63 25.48±1.34 
Total 51 49.75±9.52 20.64±2.54 
                    Age, BMI - Body mass Index expressed as mean ± standard deviation 
Table 2 – Diagnosis and Stage 
Diagnosis – Stage Number Total 
Carcinoma cervix IB1 10  
 
46 
Carcinoma cervix IB2 5 
Carcinoma cervix IIA1 1 
Carcinoma cervix IIA2 5 
Carcinoma cervix IIB 25 
Carcinoma Endometrium with endocervical involvement 
(Stage II) 
5 5 
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Out of 51 patients, 46 (90.2 %) patients had carcinoma cervix and 5 (9.8 %) 
patients had carcinoma endometrium [Table 1]. No significant differences in baseline 
characteristics - age and body mass index were observed. 
 
90% 
10% 
Diagnosis of patients who underwent Radical Hysterectomy 
Cervix Endometrium
22% 
11% 
2% 
11% 
54% 
Stages in Carcinoma cervix 
IB1 IB2 IIA1 IIA2 IIB
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In patients diagnosed as carcinoma cervix, 10, 5, 1, 5, and 25 patients had stage 
IB1, IB2, IIA1, IIA2, and II B respectively. Five patients diagnosed as carcinoma 
endometrium had endocervical involvement, clinically staged II [Table 2].   
Table 3 - Modalities of Treatment in 51 patients 
Modality RH RH + RT C + RH C+RH+RT RT + RH CRT + 
RH 
Cervix I B1 9 1 0 0 0 0 
Cervix I B2 0 0 2 2 0 1 
Cervix II A1 0 1 0 0 0 0 
Cervix II A2 0 0 1 0 2 2 
Cervix II B 0 0 3 6 2 0 
Endometrium II 
(Endocervical 
involvement) 
2 3 0 0 0 3 
Total 11(21%) 5(10%) 6(12%) 8(16%) 4(8%) 17(33%) 
RH – Radical Hysterectomy,  
RH+RT –Radical Hysterectomy followed by adjuvant therapy,  
C+RH – Preoperative Chemotherapy then Radical Hysterectomy,  
C+RH+RT – Preoperative Chemotherapy then Radical Hysterectomy followed by 
adjuvant radiotherapy, 
RT+RH – Preoperative radiotherapy then Radical Hysterectomy, and 
CRT+RH – preoperative concurrent chemotherapy and radiotherapy then Radical 
Hysterectomy 
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. Out of 51 patients, 11 (21%) patients underwent radical hysterectomy and received 
no adjuvant therapy, 5 (10%) patients underwent radical hysterectomy and received 
adjuvant radiotherapy, 6 (12%) patients received preoperative chemotherapy followed by 
radical hysterectomy and received no adjuvant therapy, 8 (16%) patients received 
preoperative chemotherapy followed by radical hysterectomy and adjuvant radiotherapy, 
4 (8%) patients received preoperative radiotherapy, 17 (33%) patients received 
preoperative concurrent chemoradiotherapy followed by radical hysterectomy and no 
adjuvant therapy ( includes 3 patients who had received definitive concurrent 
chemoradiotherapy followed by radical hysterectomy for residual disease) [Table 3]. 
Out of 25 patients diagnosed as carcinoma cervix who underwent radical 
hysterectomy without preoperative radiotherapy, 10 patients received adjuvant radiation 
(8 patients received vaginal brachytherapy, and 2 patients received external beam 
21% 
10% 
12% 
16% 
8% 
33% 
Modalites of Treatment 
RH RH+RT C+RH C+RH+RT RT+RH CRT+RH
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radiotherapy) [Table 4].   In 5 patients diagnosed as carcinoma endometrium, who 
underwent primary radical hysterectomy, 3 patients received adjuvant radiotherapy (2 
patients received both external beam radiotherapy and vaginal brachytherapy, and 1 
patient received vaginal brachytherapy alone) [Table 4].  
Table 4 - Adjuvant Radiotherapy following Radical Hysterectomy 
Carcinoma 
& 
Stage 
Radical Hysterectomy n=30 Adjuvant Radiotherapy n=13 
Primary Preoperative 
Chemotherapy 
EBRT 
+VB 
EBRT VB TOTAL 
Cervix I B1 10 0 0 1 0 1 
Cervix I B2 0 4 0 0 2 2 
Cervix II A1 1 0 0 1 0 1 
Cervix II A2 0 1 0 0 0 0 
Cervix II B 0 9 0 0 6 6 
Endometrium II 
(Endocervical 
involvement) 
5 0 2 0 1 3 
Total 16 14 2 2 9 13(43%) 
EBRT - External Beam Radiotherapy; VB - Vaginal Brachytherapy 
 
43% 
57% 
Adjuvant Radiotherapy after Radical 
Hysterectomy in 30 Patients  
Adjuvant Radiotherapy No Adjuvant Radiotherapy
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Table 5 – Complications and pathological parameters of radical hysterectomy 
 
No 
 
Parameters 
 
Carcinoma 
Cervix 
(n=46) 
Carcinoma 
Endometrium 
(n=5) 
Total 
 
(n=51) 
1 Preoperative radiotherapy ± 
Chemotherapy 
21 0 21 
2 No preoperative radiotherapy  
± chemotherapy 
25 5 30 
 Adjuvant Radiotherapy 10 3 13 
EBRT(external beam 
radiotherapy) 
2 1 3 
VB (vaginal brachytherapy) 8 0 8 
EBRT + VB 0 2 2 
3 Complications 
 Operative mortality  0 0 0 
Wound infection 
Preoperative radiotherapy  
 (n=21) 
No preoperative Radiotherapy 
(n=30) 
7 1 8 (15.7%) 
 
5 
 
0 
 
5 (23.8%) 
 
2 
 
1 
 
3 (10%) 
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Urinary bladder injury 0 0 0 
Ureteric injury 0 0 0 
Postoperative Urinary fistula 0 0 0 
4 Pathology 
 Parametrium positive 0 0 0 
Vaginal margin positive 0 0 0 
Pelvic node positive 2 0 2 
5 Recurrence within 6 months 0 1 1 
 
Table 6 Pathological parameters of carcinoma endometrium 
Carcinoma 
Endometrium 
Myometrial involvement 
( ≥ half) 
Grade Cervical involvement 
1 2 3 Stroma Gland 
5 3 1 2 2 1 2 
Out of 51 patients who underwent radical hysterectomy, there were no mortality 
and none of the patient had urinary bladder injury, ureteric injury, and postoperative 
urinary fistula. Overall wound infection rate was 15.7%. Wound infection rate in patients 
who had preoperative radiotherapy + radical hysterectomy was 23.8%, which was greater 
than in those who had no preoperative radiotherapy + radical hysterectomy (10%) 
[Table5].All patients who underwent radical hysterectomy had negative vaginal margin 
and none had microscopic/macroscopic parametrial involvement in definitive 
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histopathology. Only two patients had pelvic node positive disease. There were no loco-
regional or distant recurrence at 6 months in patients with carcinoma cervix [Table 5].  
In patients diagnosed with carcinoma endometrium only 1 patient showed 
pathological stage II and only one patient had vault recurrence at 6 month despite 
adjuvant vaginal brachytherapy [Table 5 &6].  
Subjective Analysis - Symptoms 
Table 7 - Voiding Symptoms in 51 patients 
Symptoms 1
st
 month 3
rd
 month 6
th
 month 
Straining 18 (35.3 %) 7 (13.8 %) 2 (3.9 %) 
Incontinence 12 (23.5 %) 6 (11.8 %) 1 (2.0 %) 
Urgency 7 (13.8 %) 4 (7.8 %) 0 
Dysuria 4 (7.8 %) 1(2.0%) 0 
Needed Catheterization 5 (9.8 %) 0 0 
Overall symptoms 18 (35.3 %) 7 (13.8 %) 2 (3.9 %) 
The voiding symptoms presented by patients after radical hysterectomy were 
straining, urinary incontinence, urgency, and dysuria. All patients had normal bladder 
sensation at 1
st
, 3
rd
, and 6
th
 month. The overall voiding dysfunction rate at 1
st
, 3
rd
, and 6
th
 
month after surgery were 35.3 %, 13.8 %, and  3.9% respectively.  
The most common voiding symptom was straining at 1
st
, 3
rd
, and 6
th
 month which 
manifested in 18 (35.3 %), 7 (13.8 %), and 2 (3.9%) patients respectively. Incontinence 
manifested in 12 (23.5 %), 6 (11.8%), and 1(2.0%) patients at 1
st
, 3
rd 
and 6
th
 month after 
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radical hysterectomy. Urgency manifested in 7 (13.7 %), and 4 (7.8 %) patients at 1
st
, and 
3
rd
 month respectively. 
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Dysuria manifested in 4 (7.8 %) and 1 (2.0 %) patients 1
st
, and 3
rd 
month 
respectively. None had urgency and dysuria at 6 month after radical hysterectomy.          
5 (9.8%) patients needed catheterization at 1
st
 month only. No patient needed 
catheterization at 3
rd
 and 6
th
 month [Table 7].The rates of all the voiding symptoms 
decreased at 6 months when compared to 1
st
 and 3
rd
 month after radical hysterectomy 
[Table 7]. 
 
In 11 patients who underwent radical hysterectomy alone, none of the patients had 
incontinence, urgency, dysuria at any month. None needed catheterization at any month. 
Straining manifested only in 1 (9.1 %) patient at 1
st
 month, none at 3
rd
 and 6
th
 month 
[Table 8].  
In 5 patients who underwent radical hysterectomy followed by adjuvant 
radiotherapy, none of the patients had dysuria and needed catheterization at any month. 
None had voiding symptoms at 6
th
 month. At 1
st
, and 3
rd
 month only 1 patient (20%) 
manifested straining, incontinence, and urgency [Table 8]. 
In 6 patients who received preoperative chemotherapy followed by radical 
hysterectomy none had voiding symptom at 6
th
 month. Straining and incontinence 
manifested in 2 patients (33.3%) at 1
st
 month and in 1 (16.7 %) patient at 3
rd
 month. 
Urgency manifested in 1 patient (16.7%) at 1
st
, and 3
rd
 month. Dysuria manifested in 1 
(16.7%) patient at 1
st
 month only. Only 1 (16.7%) patient needed catheterization at 1
st
 
month [Table 8]. 
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Table 8 - Voiding Symptoms 
 
Modality 
RH 
n=11 
RH +RT 
n=5 
C + RH 
n=6 
C+RH+RT 
n=8 
RT+RH 
n=4 
CRT+RH 
n=17 
Straining 
1
st
 Month 1 1 2 3 1 10 
3
rd
 Month 0 1 1 1 0 4 
6
th
 Month 0 0 0 1 0 1 
Incontinence 
1
st
 Month 0 1 2 2 0 7 
3
rd
 Month 0 1 1 0 0 4 
6
th
 Month 0 0 0 0 0 1 
Urgency 
1
st
 Month 0 1 1 1 0 4 
3
rd
 Month 0 1 0 0 0 2 
6
th
 Month 0 0 0 0 0 0 
Dysuria 
1
st
 Month 0 0 1 1 0 2 
3
rd
 Month 0 0 0 0 0 1 
6
th
 Month 0 0 0 0 0 0 
Needed Catheterization 
1
st
 Month 0 0 1 1 1 3 
3
rd
 Month 0 0 0 0 0 0 
6
th
 Month 0 0 0 0 0 0 
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In 8 patients who received preoperative chemotherapy followed by radical 
hysterectomy and adjuvant radiotherapy, only one patient (12.5%) had urgency, dysuria, 
and needed catheterization at 1
st
 month and none at 3
rd
 and 6
th
 month. Incontinence 
manifested in 2 patients (25%) at 1
st
 month only and none at 3
rd
 and 6
th
 month. Straining 
manifested in 3 patients (37.5 %) in 1
st
 month and 1 patient (12.5%) at 3
rd
 and 6
th
 month 
[Table 8]. 
In 4 patients who received preoperative radiotherapy followed by radical 
hysterectomy only one patient (25%) manifested straining at 1
st
 month only, not at 3
rd
or 
6
th
 month. None manifested incontinence, urgency, and needed catheterization at any 
month. None had dysuria at any month [Table 8]. 
In 17 patients who received preoperative concurrent chemoradiotherapy 10 
patients (58.8%), 4 patients (23.5%) and 1 patient (5.9%) had straining at 1
st
, 3
rd
 and 6
th
 
month respectively. Incontinence manifested in 7(41.2%), 4 (23.5%), and 1 (5.9) patient 
at 1
st
, 3
rd
, and 6
th
 month respectively. Urgency manifested in 4 (23.5%) and 2 (11.8%) 
patients at 1
st
, and 3
rd
 month respectively and none at 6
th
 month. Dysuria manifested in 2 
(11.8%) and 1 (5.9%) patient at 1
st
, and 3
rd
 month respectively and none at 6
th
 month 
[Table 8]. 
The association of the voiding dysfunction symptom - straining between 
preoperative radiotherapy and no preoperative radiotherapy followed by radical 
hysterectomy was statistically significant only at 1
st
 month but not at 3
rd
, and 6
th
 month 
[Table 9].  
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Table 9 - Comparison of Voiding Symptoms                                             
Preoperative Radiotherapy versus No Preoperative Radiotherapy 
Symptoms RT ± C  +  RH C ± RH ± RT p Value 
1
st
 month 
Straining 11 7 0.0417 
Incontinence 7 5 0.1956 
Urgency 4 3 0.4267 
Dysuria 2 2 1 
Catheterization 3 2 0.637 
3rd month 
Straining 4 3 0.4267 
Incontinence 4 2 0.2144 
Urgency 2 2 1 
Dysuria 1 0 0.4188 
Catheterization 0 0 1 
6th month 
Straining 1 1 1 
Incontinence 1 0 1 
Urgency 0 0 1 
Dysuria 0 0 1 
Catheterization 0 0 1 
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Table 10 - Comparison of Voiding Symptoms                                                    
Adjuvant Radiotherapy versus no Adjuvant Radiotherapy 
Symptoms Adjuvant RT No Adjuvant RT p Value 
1
st
 month 
Straining 
4 3 0.6656 
Incontinence 
3 2 0.6278 
Urgency 
2 1 0.5645 
Dysuria 
1 1 1 
Catheterization 
1 1 1 
3rd month 
Straining 
2 1 0.5645 
Incontinence 
1 1 1 
Urgency 
1 1 1 
Dysuria 
0 0 1 
Catheterization 
0 0 1 
6th month 
Straining 
1 0 0.4333 
Incontinence 
0 0 1 
Urgency 
0 0 1 
Dysuria 
0 0 1 
Catheterization 
0 0 1 
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Table 11- Comparison of Voiding Symptoms                                              
Preoperative Chemotherapy versus no Preoperative Chemotherapy 
Symptoms RH C+RH p Value 
1
st
 month 
Straining 
1 2 0.5147 
Incontinence 
0 2 0.098 
Urgency 
0 1 0.3333 
Dysuria 
0 1 0.3333 
Catheterization 
0 1 0.3333 
3rd month 
Straining 
0 1 0.3529 
Incontinence 
0 1 0.3333 
Urgency 
0 0 1 
Dysuria 
0 0 1 
Catheterization 
0 0 1 
6th month 
Straining 
0 0 1 
Incontinence 
0 0 1 
Urgency 
0 0 1 
Dysuria 
0 0 1 
Catheterization 
0 0 1 
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The association of other voiding symptoms between preoperative radiotherapy and 
no preoperative radiotherapy followed by radical hysterectomy was not statistically 
significant at 1
st
, 3
rd
, and 6
th
 month [Table 9].  
The association of voiding symptoms between adjuvant radiotherapy and no 
adjuvant radiotherapy after radical hysterectomy was not statistically significant at 1
st
, 3
rd
, 
and 6
th
 month [Table 10].    
The association of voiding symptoms between preoperative chemotherapy and no 
preoperative chemotherapy was not statistically significant at 1
st
, 3
rd
, and 6
th
 month 
[Table 11].  
Table 12 - Comparison of chemotherapy and dysuria 
Dysuria RH , RH + RT ,   
RT + RH 
11+5+4 = 19 
C + RH , C+RH+RT , 
CRT + RH 
6+8+17 = 31 
p value 
1
st
 month 0 4 0.2839 
3rd month 0 1 1 
6th month 0 0 1 
 
Table 13 - Comparison radiotherapy and dysuria 
Dysuria RH , C + RH 
11+ 6= 17 
RH + RT ,  RT + RH,  
C+RH+RT , CRT + RH 
5+4+8+17 = 34 
p value 
1
st
 month 1 3 1 
3rd month 0 1 1 
6th month 0 0 1 
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The association of dysuria and chemotherapy was not statistically significant at 1
st
, 
3
rd
, and 6
th
 month [12]. 
The association of dysuria and radiotherapy was not statistically significant at 1
st
, 
3
rd
, and 6
th
 month [13]. 
Objective analysis - Uroflowmetry parameters 
Table 14 – Uroflowmetry Parameters after Radical Hysterectomy in 51 Patients 
Parameters Preoperative 1
st
 month 
(p value) 
3
rd
month 
(p value) 
6
th
 month 
(p value) 
VV 281±22 266±32(0.110) 271±33(0.188) 278±26(0.520) 
Q Max 21.7±1.9 20.6±2.1(0.011) 21.1±2.1(0.016) 21.4±2.1(0.045) 
Q Avg 10.3±0.4 9.9±0.7(0.171) 10.0±0.4(0.101) 10.1±0.4(0.082) 
PVR 21.9±16.0 35.2±32.6(0.058) 26.7±22.3(0.171) 22.8±19.3(0.936) 
All data expressed as mean ± standard deviation; p value – Wilcoxon signed rank test 
VV= Voided volume (mL); Q Max=Maximum flow rate (mL/sec); QAvg=Average flow 
rate (mL/sec); PVR=Post-void residual urine (mL). 
In 51 patients who underwent radical hysterectomy, the preoperative voided 
volume, maximal flow rate, average flow rate and post-void residual urine were 281±22, 
21.7±1.9, 10.3±0.4, and 21.9±16.0 respectively. At 1
st
 month, 3
rd
 month and 6
th
 month 
after radical hysterectomy these parameters were 266 ± 32, 20.6 ± 2.1, 9.9 ± 0.7, &35.2 ± 
32.6; 271 ± 33, 21.1 ± 2.1, 10.0 ± 0.4, & 26.7 ± 22.3; and 278 ± 26, 21.4 ± 2.1, 10.1 ± 
0.4, & 22.8 ± 19.3 respectively [Table14]. 
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Overall uroflow parameters after radical hysterectomy 
 
 
 
In comparison of preoperative data with 1
st
, 3
rd
, and 6
th
 month data, the mean value 
of voided volume, maximum flow rate and average flow rate decreased; and post-void 
residual urine increased [Table14].  
In comparison of preoperative data with 1
st
, 3
rd
 and 6
th
 month data, only maximal 
flow rate revealed a statistically significant difference (p < 0.05). Other parameters 
voided volume, average flow rate and post-void residual urine were not significant at 1
st
, 
3
rd
, and 6
th
 month when compared with preoperative data [Table 14]. 
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Table 15 - Comparison of uroflowmetry parameters between preoperative 
radiotherapy ± chemotherapy and no preoperative radiotherapy ± chemotherapy in 
radical hysterectomy 
Parameters Preoperative 1
st
 month  
(p value) 
3
rd
 month 
(p value) 
6
th
 month 
(p value) 
Group I: Preoperative Radiotherapy  ± chemotherapy + RH  n=21 
VV 286±22 270±32(0.289) 275±33(0.429) 288±27(0.569) 
Q Max 21.5 ±2.0 19.9±1.8 (0.012) 20.5± 1.4 (0.024) 20.9±1.9 (0.041) 
QAvg 10.4±0.4 9.9±0.7(0.408) 10.1±0.4(0.491) 10.2±0.4(0.471) 
PVR 20.5±16.8 34.8±33.0(0.211) 27.4±22.6(0.171) 23.6±18.4(0.592) 
Group II: No Preoperative Radiotherapy  ± chemotherapy + RH  n=30 
VV 277±21 262±32(0.121) 270±33(0.512) 273±23(0.313) 
Q Max 21.9 ± 1.9 21.1 ± 2.1(0.298) 21.5 ± 2.3(0.222) 21.7 ± 2.2(0.373) 
QAvg 10.3±0.5 9.9±0.7(0.293) 10.0±0.5(0.143) 10.1±0.5(0.109) 
PVR 22.8±15.7 35.5±32.8(0.144) 26.2±22.4(0.497) 22.3±20.2(0.737) 
All data expressed as mean ± standard deviation 
To study the effect of preoperative radiotherapy in radical hysterectomy, the study 
population was divided into two groups namely group I with patients who underwent 
radical hysterectomy after preoperative radiotherapy with / without chemotherapy, and 
the group II with patients who underwent radical hysterectomy with/without preoperative 
chemotherapy but without preoperative radiotherapy. It was found that the maximum 
flow rate was the only parameter which was significant in Group I at 1
st
, 3
rd
, and 6
th
month 
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when compared with preoperative data.  Other parameters voided volume, average flow 
rate and post-void residual urine were not significant at 1
st
, 3
rd
, and 6
th
 month when 
compared with preoperative data [Table 15]. 
Table 16 - Comparison of uroflowmetry parameters between adjuvant radiotherapy 
and no adjuvant radiotherapy in radical hysterectomy (group II- no preoperative 
radiotherapy ± chemotherapy) 
Parameters Preoperative 1
st
 month  
(p value) 
3
rd
 month 
(p value) 
6
th
 month 
(p value) 
Group II: No Preoperative Radiotherapy  ± chemotherapy + RH 
A: Adjuvant Radiotherapy n=13 
VV  276±20 268±36(0.808) 270±35(0.861) 270±25(0.718) 
Q Max 22.0 ± 1.8 20.8 ±1.7(0.054) 21.3 ± 2.1(0.017) 21.6 ± 2.2(0.052) 
QAvg 10.3±0.6 9.8±0.8(0.147) 9.9±0.5(0.181) 10.1±0.4(0.166) 
PVR  25.0±14.9 31.9±31.0(0.608) 24.2±21.4 (0.887) 24.2±22.3(0.774) 
Group II: No Preoperative Radiotherapy  ± chemotherapy + RH 
B:No Adjuvant Radiotherapy n=17 
VV  278±23 258±28(0.090) 269±32(0.428) 274±22(0.196) 
Q Max 21.9±2.0 21.4 ± 2.3(0.537) 21.7 ± 2.6 (0.600) 21.7 ± 2.2(0.775) 
QAvg 10.3±0.4 9.9±0.6(0.942) 10.1±0.5(0.505) 10.1±0.5(0.404) 
PVR  21.2±16.5 38.2±34.8(0.171) 27.6±23.7(0.260) 20.8±19.0(0.858) 
All data expressed as mean ± standard deviation 
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To compare the effect of adjuvant radiotherapy, the Group II was sub-divided into    
Group A (received adjuvant radiotherapy) and Group B (received no adjuvant 
radiotherapy). In Group A, only the parameter maximum flow rate was found significant 
in 3rd month and not in 1
st
 and 6
th
 month when compared to preoperative data.  Other 
parameters voided volume; average flow rate; and post-void residual urine were not 
significant in 1
st
, 3
rd
 and 6
th
 months when compared to preoperative data [Table 16]. 
Table 17 - Comparison of uroflowmetry parameters between no preoperative 
chemotherapy and preoperative chemotherapy followed by radical hysterectomy 
and no adjuvant radiotherapy 
Parameters Preoperative 1
st
 month  
(p value) 
3
rd
 month 
(p value) 
6
th
 month 
(p value) 
Radical Hysterectomy (RH) + No Adjuvant Radiotherapy n=11 
VV  280±23 268±23(0.442) 281±25(0.464) 277±23(0.448) 
Q Max 21.8±1.6 21.8  ±2.0(0.674) 21.7±2.1(0.596) 21.6±1.8(0.752) 
QAvg 10.3±0.3 10.0±0.5(0.914) 10.1±0.4(0.532) 10.1±0.4(0.527) 
PVR  21.7±17.5 57.3±34.5(0.283) 28.2±25.3(0.297) 21.4±21.3(0.916) 
 Preoperative Chemotherapy + RH + No Adjuvant Radiotherapy n=6 
VV  273±24 238±26(0.115) 248±37(0.072) 268±22(0.180) 
Q Max 22±2.7 20.6±3(0.247) 21.6±3.5(0.757) 21.9±3.0(0.474) 
QAvg 10.4±0.4 9.8±0.8(0.784) 10±0.6(0.917) 10.2±0.7(0.371) 
PVR  20.8±16.3 40.0±38.5(0.416) 26.7±22.7(0.715) 20.0±15.5(0.785) 
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None of the uroflow parameters were found to be significant when compared 
preoperative chemotherapy and no preoperative chemotherapy followed by radical 
hysterectomy at 1
st
, 3
rd
, and 6
th
 month [Table 17]. 
Comparison of subjective and objective analysis of urinary bladder morbidity 
The association of straining and uroflow curve was considered to be statistically 
significant at 1
st
, 3
rd
, and 6
th
 month [18]. 
Table 18- Comparison of Straining and Uroflow Curve 
 
Straining 
Uroflow curve Total 
Abnormal Normal 
1
st
 month (p value= 0.0001) 
Present 12 6 18 
Absent 4 29 33 
Total 16 35 51 
3
rd
 month (p value = 0.0042) 
Present 4 3 7 
Absent 3 41 44 
Total 7 44 51 
6
th
month (p value =0.0047) 
Present 2 0 2 
Absent 2 47 49 
Total 4 47 51 
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Comparison of Straining and Uroflow Curve  
1
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The sensitivity, specificity, positive predictive value and negative predictive value 
of uroflow curve in identifying straining was 75%, 82.8%, 66.7%, & 87.9% ; 57.1%, 
93.2%, 57.1%, & 93.2% ; and 50%, 95.9%, 100%, & 100% at 1
st
, 3
rd
, and 6
th
 month  
respectively [Table18]. 
Table 19 - Comparison of Straining and Maximum Flow Rate 
Straining Maximum Flow Rate  Total 
Abnormal  Normal 
1
st
 Month (p value =1) 
Present 0 18 18 
Absent 0 33 33 
Total 0 51 51 
3
rd
 Month (p value =1) 
Present 0 7 7 
Absent 0 44 44 
Total 0 51 51 
6
th
 Month (p value =1) 
Present 0 2 2 
Absent 0 49 49 
Total 0 51 51 
The association between maximum flow rate and straining was not statistically 
significant at 1
st
, 3
rd
, and 6
th
 month [Table19]. 
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Table 20 - Comparison of Straining and Post void-residual urine 
Straining Post-void Residual Urine Total 
Abnormal Normal 
1
st
 Month (p value 0.0002) 
Present 11 7 18 
Absent 5 28 33 
Total 16 35 51 
3
rd
 Month (p value 0.0276) 
Present 3 4 7 
Absent 3 41 44 
Total 6 45 51 
6
th
 Month (p value 0.1493) 
Present 1 1 2 
Absent 3 46 49 
Total 4 47 51 
 
The association between post-void residual urine and voiding symptom straining 
was statistically significant at 1
st
 month (p value 0.0022), and 3
rd
 month (p value 0.0342) 
but was not statistically significant at 6
th
 month (p value 0.3572) [Table 20]. 
At 1
st
 month abnormal post-void residual urine had sensitivity, specificity, positive 
predictive value and negative predictive value of 68.8%, 80%, 61.1% and 84.8% 
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respectively in identifying voiding symptom straining [Table 20].At 3
rd
 month abnormal 
post-void residual urine had sensitivity, specificity, positive predictive value and negative 
predictive value of 50%, 91.9%, 42.9% and 93.2% respectively in identifying voiding 
symptom straining [Table 20]. 
 
Table 21 - Comparison of Post void residual urine with Catheterization 
Catheterization 
 
Post-Void Residual Urine Total 
Abnormal  Normal 
1
st
 month (p value= 0.0195) 
Needed 5 0 5 
Not Needed 16 30 46 
Total 21 30 51 
 
The association between post-void residual urine and catheterization was 
statistically significant at 1
st
 month (p value 0.0195), but not statistically significant at 3
rd
 
and 6
th
 month [Table 21].  
Post-void residual urine had sensitivity, specificity, positive predictive value and 
negative predictive value of 23.8%, 100%, 100% and 65.2% in identifying patients who 
needed catheterization at 1
st
 month [Table 21]. 
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Comparison of Straining and Post void-residual urine 
1
st
 month 
 
3
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Comparison of Post void-residual urine and catheterization at 1
st
 month 
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Table 22 - Comparison of Straining, Post-void residual urine and Catheterization 
Comparison Straining Present n = 18 Straining Absent n = 33  
Total Catheterization Post-Void Residual Urine Post-Void Residual Urine 
Abnormal Normal Abnormal Normal 
1
st
 Month 
Needed 5 0 0 0 5 
Not Needed 6 7 5 28 46 
Total 11 7 5 28 51 
 
In patients who had voiding symptom straining, the association between post-void 
residual urine and catheterization was not statistically significant at 1
st
 month                  
(p value = 0.1013). In patients who did not have voiding symptom straining, the 
association between post-void residual urine and catheterization was not statistically 
significant at 1
st
 month (p value = 1).  
Table 23 - Urine Culture in Patients with Dysuria 
 
Month 
 
Dysuria present 
Urine Culture 
Positive Negative 
1
st
 4 0 4 
3
rd
 1 0 1 
 
None had dysuria at 6
th
 month. None of the patients with dysuria had positive 
urine culture at 1
st
 and 3
rd
 month [Table 23].  
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DISCUSSION 
 
The incidence of urinary bladder dysfunction after radical hysterectomy for uterine 
cervical cancer is known to be between 70 % and 85 % [105, 106]. A few studies have 
suggested that the bladder dysfunction after radical hysterectomy may be transient and 
that bladder function may recover to baseline within 6 to 12 months [107]. In this study 
the rate of overall voiding symptom after type III radical hysterectomy was 35.3% at 1
st
 
month which decreased to 13.8% at 3
rd
 month and 3.9% at 6
th
 month. This showed 
improved voiding with time up to 6
th
 month in this study. All patients had normal urinary 
bladder sensation after type III radical hysterectomy. In this study, the most common 
voiding symptom was straining, followed by incontinence, at 1
st
, 3
rd
, and 6
th
 month.  
However, Sekido et al. reported postoperative urinary tract dysfunction that was 
sustained for more than 10 years [108]. 
 
In general, urinary bladder dysfunction after radical hysterectomy is known to be 
related to denervation of the autonomic nerve during surgical procedures. Chen et al. 
suggested that post-hysterectomy changes in lower urinary tract function may be related 
to the partial denervation of the pelvic autonomic nerves [71]. It has also been suggested 
by Zullo et al. that the most important factor for postoperative bladder dysfunction was 
the resection of vaginal and paravaginal tissue which supports the urinary bladder [75].  
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There was no operative mortality rate for type III radical hysterectomy in this 
study which was comparable to Meigs hysterectomy operative mortality rate [47]. There 
were no urinary bladder injury and no ureteric injury. No postoperative urinary fistula 
occurred, even though preoperative and postoperative radiotherapy was given. Overall 
wound infection rate was 15.7%. There were no recurrences in carcinoma cervix patients 
who underwent radical hysterectomy. Only 1 patient had vault recurrence in carcinoma 
endometrium, even though that patient received adjuvant vaginal brachytherapy. 
 
Lin et al. reported that there was no significant difference in the results of 
urodynamic study between a radical hysterectomy only and a combination group that 
underwent radical hysterectomy and radiotherapy [109]. By contrast, Chauang and Kuo 
reported that patients who were treated by radical hysterectomy with radiotherapy had 
worse bladder morbidity. Thus, controversy remains about the effect of radiotherapy, and 
it is very difficult to solve this problem [110].  
 
In this study, the association of straining between patients who received 
preoperative radiotherapy ± chemotherapy followed by radial hysterectomy and those 
who received no preoperative radiotherapy ± chemotherapy followed by radical 
hysterectomy showed a statistical significance at 1
st
 month only, but not at 3
rd
 and 6
th
 
month. Other voiding symptoms didn‘t show a statistical significance at 1st, 3rd, and       
6
th
 month.  
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The association of voiding symptoms between patients who received adjuvant 
radiotherapy after radical hysterectomy and no adjuvant therapy after radical 
hysterectomy didn‘t showed a statistical significance at 1st, 3rd, and 6th month. The 
association of voiding symptoms between patients who received preoperative 
chemotherapy followed by radical hysterectomy & no adjuvant therapy and no 
preoperative therapy followed by radical hysterectomy & no adjuvant therapy didn‘t 
showed a statistical significance at 1
st
, 3
rd
, and 6
th
 month. 
 
In this study, the decrease in maximum flow rate following radical hysterectomy 
showed a statistical significance at 1
st
, 3
rd
, and 6
th
 month when compared with 
preoperative data, even though the actual mean value was not abnormal. Other 
parameters voided volume, average flow rate, and post-void residual urine were not 
statistically different at 1
st
, 3
rd
, and 6
th
 month when compared with preoperative data.   
 
It was observed that, patients who underwent radical hysterectomy with 
preoperative radiotherapy, had a decrease only in maximum flow rate only at 1
st
, 3
rd
, and 
6
th
 month with statistically significant difference when compared with patients who 
underwent radical hysterectomy without preoperative radiotherapy. Other parameters like 
voided volume, average flow rate and post void residual urine didn‘t showed a statistical 
significance at 1
st
, 3
rd
 and 6
th
 month. .  
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Comparing patients who had received adjuvant radiotherapy versus no adjuvant 
radiotherapy following radical hysterectomy, patients who received adjuvant 
radiotherapy had a statistical significance decrease in maximum flow rate at 3
rd
month 
only, as adjuvant radiotherapy was started 4 to 6 weeks after radical hysterectomy. Other 
parameters were not significant at any time. The results of this study support the theory 
that radiotherapy may result in the deterioration of postoperative bladder function and it 
may recover to baseline within 6
th
month. 
 
Comparing preoperative chemotherapy and no preoperative chemotherapy in 
patients who underwent radical hysterectomy, none of the uroflow parameters showed a 
statistical significance at 1
st
, 3
rd
, and 6
th
 month. 
 
Even though the maximum flow rate was decreased at 6 month with statistically 
significance (p value 0.045), the mean value was not  abnormal, and voiding symptoms 
improved at 6
th
month (3.9%) when compared to 1
st
 month (35.3%) and 3
rd
 month 
(13.8%), there was no statistical significant association between uroflow parameter 
maximum flow rate  and straining symptom. In spite of this, uroflow curve was found be 
abnormal in symptomatic patients who had straining with statistical significance at 1
st
, 
3
rd
, and 6
th
 month. 
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Incontinence rate decreased from 23.5% to 2% at 6
th
 month as pelvic floor 
exercises were reinforced to patients. Urgency completely disappeared at 6
th
 month from 
13.7% at 1
st
 month and 7.8% at 3
rd
 month. Dysuria manifested in 9.8% and 2% at 1
st
 and 
3
rd
 month respectively and none at 6
th
 month. None of the patients with dysuria had a 
positive urine culture. Dysuria never manifested in patients who were not exposed to 
chemotherapy in their treatment but unable to prove statistical significance. Only 9.8% 
needed catheterization at 1
st
 month and none at 3
rd
 and 6
th
 month. 
In this study, post-void residual urine after type III radical hysterectomy at 1
st
, 3
rd
, 
and 6
th
 month was not significant when compared with preoperative data. However the 
association of post-void residual urine with voiding symptom straining showed statistical 
significance at 1
st
 and 3
rd
 month but not at 6
th
 month. The association of post-void 
residual urine and the need of catheterization showed statistical significance at 1
st
 month. 
But in patients with straining the association of post-void residual urine and the need of 
catheterization was not found to be statistically significant.  
 
This study has clinical significance because few studies [111] have assessed the 
effect of radiotherapy preoperatively as well as postoperatively and chemotherapy by use 
of uroflowmetry and post-void residual urine. Considering that role of radiotherapy is 
inevitable for carcinoma cervix and endometrium, our final goal of treatment should be 
gaining not only good oncologic outcomes but also the prevention of lower urinary tract 
morbidity.  
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LIMITATIONS OF THE STUDY 
 
1. The artificial situation of the urodynamic laboratory might produce a non-
physiologic result. 
2. The absence of a specific abnormality during urodynamic testing does not exclude 
its existence. 
3. Only non-invasive uroflowmetry and measured of post-void residual urine by 
transabdominal ultrasound was used in this study, invasive urodynamic study such 
as cystometry and pressure flow studies  were not used and measurement of post-
void residual urine was not measured by catheterization. 
4. Inconsistent reproducibility of test results in the same patient when repeated. 
5. Wide range of physiologic values in normal, asymptomatic patients. 
6. Only short-term (6 months) urinary bladder morbidity was assessed with small 
sample size (n=51) in our study. 
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CONCLUSION 
 
In conclusion, type III radical hysterectomy gives rise to transient alteration in the 
neurophysiology of the lower urinary tract. Although most of these changes return to 
normal within a certain period of time (6-12 months), it is suggested to pay attention to 
voiding symptom of straining, and the uroflow parameter of maximum flow rate, 
especially in patients who receive radiotherapy. The uroflow curve and post-void residual 
urine in also require note in patients with voiding symptom straining. 
 
This study showed that it may not always be necessary to use uroflowmetry values 
to evaluate the voiding dysfunction following radical hysterectomy, as there is wide 
range of physiologic values in asymptomatic patients and not all abnormalities in 
uroflowmetry are clinically significant. Post-void residual urine measured with non-
invasive method of ultrasound may be sufficient to identify patients who will need 
intermittent catheterization. Further studies with a larger number of patients and         
long-term follow-up are required to explore this. 
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ANATOMY OF LOWER URINARY TRACT 
Left– Gosling & Dixon; Right- Elbadawi & Coworkers 
 
 
Laplace’s Law T = P ×R ÷ (2×d)
 
  
INNERVATION OF LOWER URINARY TRACT 
 
• Sympathetic nerve fibers originate from the para-aortic sympathetic chain of 
the thoracic and lumbar nerve roots T10–L2. Postganglionic nerve fibers run to 
the superior hypogastric plexus, connect it with the pelvic plexuses, and 
innervate the bladder, bladder neck and urethra.  
• The parasympathetic splanchnic nerves originate from the sacral nerve roots 
S2–S4 and run through the pelvic plexuses to the bladder.  
• In the pelvic plexuses, parasympathetic nerves synapse with sympathetic fibres.  
• The pudendal nerve innervates the external urethral sphincter with sensory and 
motor fibers. 
  
Mechanism of storage and voiding reflexes 
A - Storage reflexes 
During the storage of urine, distension of the bladder produces low-level bladder 
afferent firing. Afferent firing in turn stimulates the sympathetic outflow to the 
bladder outlet (base and urethra) and pudendal outflow to the external urethral 
sphincter. These responses occur by spinal reflex pathways and represent “guarding 
reflexes,” which promote continence. Sympathetic firing also inhibits detrusor muscle 
and transmission in bladder ganglia 
 
B -Voiding reflexes 
At the initiation of micturition, intense vesical afferent activity activates the brainstem 
micturition centre, which inhibits the spinal guarding reflexes (sympathetic and 
pudendal outflow to the urethra). The pontine micturition centre also stimulates the 
parasympathetic outflow to the bladder and internal sphincter smooth muscle. 
Maintenance of the voiding reflex is through ascending afferent input from the spinal 
cord, which may pass through the periaqueductal gray matter (PAG) before reaching 
the pontine micturition centre. 
  
Autonomic Nerve Plexus of Pelvis 
The superior hypogastric plexus is a continuation of the aortic (inter-mesenteric) 
plexus. It divides into left and right hypogastric nerves as it enters the pelvis. The 
hypogastric and pelvic splanchnic nerves merge to form the inferior hypogastric 
plexuses, which thus consist of both sympathetic and parasympathetic fibres.  
 
Avascular Spaces of Pelvis 
 
The bladder, cervix, and rectum are surrounded by a connective tissue covering. 
Between the firm connective tissue bundles is loose connective tissue (Para spaces). 
  
CLASSIFICATION OF RADICAL HYSTERECTOMY ACCORDING TO 
PIVER, RUTLEDGE AND SMITH 
Parametrial dissection in Type I, II, & III 
Type I 
Uterosacral ligament and cardinal ligament are not removed  
Type II 
Uterosacral ligaments resected midway between the uterus and their sacral 
attachments 
Medial half of the cardinal ligaments removed 
 
TYPE III 
Uterosacral ligaments resected at their sacral attachments 
Cardinal ligaments resected at the pelvic wall 
  
OPERATIVE PICTURES – TYPE III RADICAL HYSTERCETOMY 
 
Paravesical Fossa 
 
Pararectal Fossa 
 
Pelvic lymph node dissection 
 
Ureterovesical junction 
 
Parametrium 
 
Specimen 
  
Normal uroflow curve 
Continuous, bell-shaped, smooth curve with a rapidly increasing flow rate  
 
 
 
Abnormal uroflow curve 
An intermittent flow pattern is one that has several episodes of flow increasing or 
decreasing (or ceasing completely) and is commonly secondary to abdominal straining 
or external sphincter spasm  
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PATIENT PROFORMA 
 
Name:    Age:                                 CD No:   
   
Height:         cm                            Weight:       kg                BMI: 
 
Diagnosis: 
 
Stage (FIGO/AJCC / TNM 7
th
 edition):                                          
 
Preoperative therapy - Chemotherapy / Radiotherapy / None 
 
Intraoperative Findings: 
 
Postoperative complications: 
 
Final Histopathology: 
 
Postoperative therapy - Chemotherapy / Radiotherapy / None 
 
Voiding symptoms: 
 
Symptoms Baseline 1
st
 month 3
rd
 month 6
th
 month 
Urgency     
Straining     
Urinary incontinence     
Dysuria     
Overall symptoms     
Needed catheterization     
 
Uroflowmetry:  
 
Parameters  Baseline 1
st
 month 3
rd
 month 6
th
 month 
Voided volume (ml)     
Max. flow rate (ml/s)     
Avg. flow rate  (ml/s)     
Post-void residual urine(ml)     
Urowflow curve     
 
 
